Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.20549

FORM 10-Q

(Mark one)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-17284

AIXIN LIFE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Colorado		84-1085935
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

Hongxing International Business Building 2, 14^th FL, No. 69 Qingyun South Ave., Jinjiang District

Chengdu City, Sichuan Province, China

(Address of principal executive offices)

86-313-6732526

(Issuer’s telephone number)

Securities Registered Pursuant to Section 12(g) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each Exchange on which Registered
Common Stock, $0.00001 Par Value		AIXN		OTCQX

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date: As of May 26, 2024, there were outstanding 24,999,842 shares of the registrant’s common stock.

AIXIN LIFE INTERNATIONAL, INC.

FORM 10-Q

March 31, 2024

INDEX

		Page

Special Note Regarding Forward Looking Statements		3

Part I – Financial Information		4

Item 1.	Consolidated Financial Statements	4

	Consolidated Balance Sheets	4

	Consolidated Statements of Operations and Comprehensive Loss	5

	Consolidated Statements of Stockholders’ Deficit	6

	Consolidated Statements of Cash Flows	7

	Notes to Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 4.	Controls and Procedures	34

Part II – Other Information		35

Item 1.	Legal Proceedings	35

Item 1A.	Risk Factors	35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35

Item 3.	Defaults Upon Senior Securities	35

Item 5.	Other Information	35

Item 6.	Exhibits	36

	Signatures	37

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This report contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements include, among other things, statements relating to:

	●	our goals and strategies;

	●	our future business development, financial condition and results of operations;

	●	our expectations regarding demand for, and market acceptance of, our products;

	●	our expectations regarding keeping and strengthening our relationships with merchants, manufacturers and end-users; and

	●	general economic and business conditions in the regions where we provide our services.

Also, forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and the documents that we reference and filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

Use of Certain Defined Terms

Except where the context otherwise requires and for the purposes of this report only:

the “Company,” “we,” “us,” and “our” refer to AiXin Life International., Inc. (“AiXin”) and its subsidiaries.

“Exchange Act” refers to the Securities Exchange Act of 1934, as amended;

“Hong Kong” refers to the Hong Kong Special Administrative Region of the People’s Republic of China;

“PRC,” “China,” and “Chinese,” refer to the People’s Republic of China (excluding Hong Kong and Taiwan);

“Renminbi” and “RMB” refer to the legal currency of China;

“Securities Act” refers to the Securities Act of 1933, as amended; and

“US dollars,” “dollars” and “$” refer to the legal currency of the United States.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2024			2023
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	305,027		$	443,758
Restricted cash		35,967			23,208
Accounts receivable, including related parties, net		379,845			253,586
Other receivables and prepaid expenses, including related party		187,971			170,831
Advances to suppliers		225,294			152,563
Inventory, net		459,416			441,098
Due from related parties		102,437			12,400
Total current assets		1,695,957			1,497,444

Property and equipment, net		1,551,211			1,679,675
Intangible assets, net		3,398			3,917
Security deposit		83,168			84,508
Operating lease right-of-use assets		2,125,320			1,576,814
Goodwill, net		-			-
Total assets	$	5,459,054		$	4,842,358

Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	487,931		$	478,456
Accounts payable - related party		-			1,776
Accounts payable	$	487,931		$	478,456
Unearned revenue		248,530			172,753
Taxes payable		81,108			49,249
Accrued liabilities and other payables		2,249,432			2,163,066
Government grant		907,843			923,238
Loan from third parties		83,099			84,508
Operating lease liabilities		208,842			864,519
Due to related parties		1,679,188			1,226,885
Total current liabilities		5,945,973			5,964,450
Operating lease liabilities - non-current		1,901,857			789,489
Total liabilities		7,847,830			6,753,939

Stockholders’ deficit
Undesignated preferred stock, $0.001 par value, 20,000,000 shares authorized, none issued and outstanding		-			-
Common stock, par value $0.00001 per share, 500,000,000 shares authorized; 24,999,834 shares issued and outstanding as of March 31, 2024 and December 31, 2023		250			250
Additional paid in capital		15,068,308			14,975,423
Statutory reserve		151,988			151,988
Accumulated deficit		(17,823,992	)		(17,220,392	)
Accumulated other comprehensive income		214,670			181,150
Total stockholders’ deficit		(2,388,776	)		(1,911,581	)

Total liabilities and stockholders’ deficit	$	5,459,054		$	4,842,358

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	2024			2023
	Three Months Ended March 31,
	2024			2023

Sales revenue:
Products	$	697,094		$	422,296
Room revenues		32,782			177,259
Food and beverage revenues		109,716			133,738
Others		11,967			21,420
Total revenue, net		851,559			754,713

Operating costs and expenses
Cost of goods sold		327,811			175,488
Hotel operating costs		461,079			477,794
Selling		222,233			191,273
General and administrative		360,770			413,059
Provision for (reversal of) bad debts		8,027			(43,816	)
Stock-based compensation		92,885			92,885
Total operating costs and expenses		1,472,805			1,306,683

Loss from operations		(621,246	)		(551,970	)

Non-operating income (expenses)
Interest income		114			289
Other income		18,802			24,861
Other expenses		(1,270	)		(2,507	)
Total non-operating income, net		17,646			22,643

Loss before income tax		(603,600	)		(529,327	)

Income tax expense		-			457

Net loss		(603,600	)		(529,784	)

Other comprehensive items
Foreign currency translation gain		33,520			24,542

Comprehensive loss	$	(570,080	)	$	(505,242	)

Loss per share - basic and diluted	$	(0.024	)	$	(0.021	)

Weighted average shares outstanding - basic and diluted		24,999,834			24,999,842

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

	Shares		Amount		capital		reserves		deficit			income		Total
	Common Stock				Additional paid in		Statutory		Accumulated			Accumulated other comprehensive
	Shares		Amount		capital		reserves		deficit			income		Total

Balance at December 31, 2023		24,999,834	$	250	$	14,975,423	$	151,988	$	(17,220,392	)	$	181,150	$	(1,911,581	)
Stock-based compensation		-		-		92,885		-		-			-		92,885
Net loss		-		-		-		-		(603,600	)		-		(603,600	)
Foreign currency translation gain		-		-		-		-		-			33,520		33,520
Balance at March 31, 2024		24,999,834	$	250	$	15,068,308	$	151,988	$	(17,823,992	)	$	214,670	$	(2,388,776	)

Balance at December 31, 2022		24,999,842	$	250	$	14,458,583	$	151,988	$	(15,249,858	)	$	172,849	$	(466,188	)
Balance		24,999,842	$	250	$	14,458,583	$	151,988	$	(15,249,858	)	$	172,849	$	(466,188	)
Stock-based compensation		-		-		92,885		-		-			-		92,885
Disposal of subsidiary		-		-		-		-		120,160			-		120,160
Net loss		-		-		-		-		(529,784	)		-		(529,784	)
Foreign currency translation gain		-		-		-		-		-			24,542		24,542
Balance at March 31, 2023		24,999,842	$	250	$	14,551,468	$	151,988	$	(15,659,482	)	$	197,391	$	(758,385	)
Balance		24,999,842	$	250	$	14,551,468	$	151,988	$	(15,659,482	)	$	197,391	$	(758,385	)

AIXIN LIFE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	2024			2023
	Three Months Ended March 31,
	2024			2023

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(603,600	)	$	(529,784	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		106,299			104,561
Provision for (reversal of) bad debts		8,027			(43,816	)
Provision for inventory reserve		9,405			18,502
Operating lease expense		233,070			210,334
Stock-based compensation		92,885			92,885
Deferred tax		-			457
Changes in assets and liabilities:
Accounts receivable		(38,491	)		176,944
Accounts receivable - related party		(100,603	)		-
Accounts receivable		(38,491	)		176,944
Other receivables and prepaid expenses		(20,080	)		(50,416	)
Advances to suppliers		(39,498	)		49,587
Inventory		(35,192	)		(200,787	)
Security deposit		(70	)		-
Accounts payable		17,528			42,332
Accounts payable - related party		(1,754	)		(167,209	)
Accounts payable		17,528			42,332
Unearned revenue		78,999			192,689
Taxes payable		32,823			(59,279	)
Payment of lease liabilities		(325,498	)		(186,473	)
Accrued liabilities and other payables		124,299			(123,208	)
Net cash used in operating activities		(461,451	)		(472,681	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash disposed at disposal of subsidiary		-			(3,435	)
Purchase of property and equipment		(41,053	)		(1,746	)
Net cash used in investing activities		(41,053	)		(5,181	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Change in advance from related parties		383,802			437,560
Net cash provided by financing activities		383,802			437,560

EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(7,270	)		2,836

NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(125,972	)		(37,466	)

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD		466,966			619,900

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	$	340,994		$	582,434

Supplemental Cash flow data:
Income tax paid	$	-		$	-
Interest paid	$	-		$	-

AIXIN LIFE INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Aixin Life International, Inc. (the “Company” or “Aixin Life” or “we”) was incorporated under the laws of the State of Colorado on December 30, 1987. On February 2, 2017, Mr. Quanzhong Lin (Mr. Lin) purchased 65.0% of the Company’s outstanding shares from China Concentric Capital Group for $300,000, pursuant to a Stock Purchase Agreement dated December 21, 2016, which resulted in a change in control of the Company.

On December 12, 2017, pursuant to a Share Exchange Agreement, in consideration for all of the outstanding shares of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), the Company issued to Mr. Lin, the sole stockholder of AiXin BVI, shares of common stock then representing 71% of the outstanding of common stock of the Company.

As a result of the Share Exchange, AiXin BVI became the Company’s wholly-owned subsidiary, and the Company now owns all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhonghong”), which markets and sells premium-quality nutritional products in China.

AiXin BVI was incorporated on September 21, 2017 as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 as an intermediate holding company. AiXinZhonghong was established in the People’s Republic of China (“PRC”) on March 4, 2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXinZhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

For accounting purposes, the acquisition of AiXin BVI was accounted for as a reverse acquisition and treated as a recapitalization of the Company effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical consolidated financial statements of AiXinZhonghong are now the historical consolidated financial statements of the Company. The assets and liabilities of AiXinZhonghong were brought forward at their book value and no goodwill was recognized.

Effective February 1, 2018, the Company changed its name to AiXin Life International, Inc. (“Aixin Life”).

The Company, through its indirectly owned subsidiary, AiXinZhonghong, develops and distributes consumer products by offering a line of nutritional products. The Company sells the products through exhibition events, conferences, and person-to-person marketing. The Company’s business mainly focuses on a proactive approach to its customers such as hosting events for clients, which it believes is ideally suited to marketing its products because sales of nutrition products are strengthened by ongoing personal contact and support, coaching and education of its clients, as to the benefits of a healthy and active lifestyle.

On May 25, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Hotel Purchase Agreement”) with Chengdu Aixin Shangyan Hotel Management Co., Ltd (“Aixin Shangyan Hotel”), and its two shareholders Quanzhong Lin and Yirong Shen (“Transferor”). Pursuant to the Hotel Purchase Agreement, Aixin Life purchased 100% ownership of Aixin Shangyan Hotel from Transferor. Eighty percent of the equity of Aixin Shangyan Hotel was owned by Mr. Lin, and the remaining balance was owned by Ms. Shen. Under the terms of the Hotel Purchase Agreement, Aixin Life purchased all of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1.16 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to the Transferor after December 31, 2020 and will be increased by an amount equal to any amounts contributed to Aixin Shangyan Hotel by the Transferor after December 31, 2020. The acquisition was completed in July 2021.

On June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Pharmacies Purchase Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, “Aixintang Pharmacies”) and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owned in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling Li. Pursuant to the Pharmacies Purchase Agreement, AiXin HK purchased all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million (the “Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by an amount contributed to any of the Aixintang Pharmacies by the Transferor after such date. The acquisition was completed in September 2021.

On July 19, 2022, AiXin HK entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, (“Yunnan Shengshengyuan”) and Yun Chen (together, the “Sellers”), the shareholders of Yunnan Runcangsheng Technology Company Ltd. (“Runcangsheng”). Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun Chen. Pursuant to the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Runcangsheng for an aggregate purchase price of $4,418,095 (RMB 31,557,820), adjusted by $116,802 the amount equal to the initial net worth minus the audited net worth. In addition to transferring their respective equity interest in Runcangsheng by the Sellers, both Sellers agree to forgive any loans Runcangsheng due to them. The acquisition was completed on September 30, 2022.

On February 17, 2023, the Company effected a 1 for 2 reverse stock split. As a result of the reverse split, every two shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.00001 per share. The Company has approximately 24,999,834 shares of outstanding common stock after the effect of reverse stock split and the elimination of fractional shares. All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

The accompanying consolidated financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi (“RMB”). The accompanying consolidated financial statements are translated from RMB and presented in U.S. dollars (“USD”).

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, AiXin HK, AiXinZhonghong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng. Intercompany transactions and accounts were eliminated in consolidation. These unaudited interim financial statements should be read in conjunction with the annual consolidated financial statements and the accompanying notes contained in our Annual Report on Form 10-K for the year ended December 31, 2023.

Unaudited Interim Financial Information

These unaudited interim financial statements have been prepared in accordance with GAAP for interim financial reporting and the rules and regulations of the Securities and Exchange Commission that permit reduced disclosure for interim periods. Therefore, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, all adjustments of a normal recurring nature necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been made. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the year ending December 31, 2024.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on, among other things, the Company’s ability to operate profitably, to generate cash flows from operations, and to pursue financing arrangements to support its working capital requirements.

The Company has suffered net losses of $603,600 and $529,784 for the three months ended March 31, 2024 and 2023, respectively, and used net cash in operating activities of $461,451 and $472,681 for the three months ended March 31, 2024 and 2023, respectively, and has an accumulated deficit of $17,823,992 as of March 31, 2024. These facts and conditions raise substantial doubt about the Company’s ability to continue as a going concern. From January 1, 2024 through March 31, 2024, the Company’s cash and cash equivalents decreased from $443,758 to $305,027 mainly due to operating losses, and the use of cash to support operating activities.

Management believes that it has developed a liquidity plan, summarized below, that, if executed successfully, should provide sufficient liquidity to meet the Company’s obligations as they become due for a reasonable period of time, and allow the development of its core business. The plan includes:

● Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

● Raising cash through loans from related parties and potential equity offerings.

While the Company’s management believes that the measures in its liquidity plan including those described above will be adequate to satisfy its liquidity requirements for the twelve months after the date that these financial statements are issued, there is no assurance that the liquidity plan will be successfully implemented. Failure to successfully implement the liquidity plan may have a material adverse effect on its business, results of operations and financial position, and may adversely affect its ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.

Global Uncertainties

The Company’s liquidity may be adversely impacted by various risks and uncertainties, including, but not limited to future and current impacts of global events such as a widespread health crisis, the continuation of the war in the Ukraine or the conflict in Palestine, the outbreak of another conflict or the expansion of the conflict in Palestine to other countries, the ongoing tensions between the United States and China, the Russian Federation and certain countries in the Middle East, increases in inflation, and other risks detailed in the Company’s Annual Report on Form 10-K or other reports filed with the Securities and Exchange Commission.

While the invasion of Ukraine, the conflict in Palestine and responses thereto have not interrupted the Company’s operations, these or future developments which disrupt the international financial markets could make it difficult to access debt and equity capital on attractive terms, if at all, and impact the Company’s ability to fund business activities, including proposed acquisitions.

Use of Estimates

In preparing consolidated financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

Significant estimates required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash

The restricted cash was cash maintained in temporarily frozen bank accounts held by Aixintang Pharmacy and its branches by the court for a judgement against Aixintang Pharmacy (see Note 17 – litigation).

Accounts Receivable

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2024 and December 31, 2023, the bad debt allowance was $87,287 and $80,640 respectively.

The following table summarizes the activity related to the Company’s accounts receivable allowance for doubtful accounts for the three months ended March 31, 2024 and 2023:

	2024			2023
	For the three months ended March 31,
	2024			2023

Beginning balance	$	80,640		$	272,550
Provision for bad debts		8,027			-
Recoveries/Write offs		-			(43,816	)
Effect of translation		(1,380	)		1,342
Ending balance	$	87,287		$	230,076

Inventories

Inventories mainly consists of health supplements, drugs, pharmaceutical and nutritional products, food and beverage, hotel supplies and consumables. Inventories are valued at the lower of average cost or market, cost being determined on a moving weighted average method at the end of the month. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories to market value, if lower. The Company recorded provision for inventory reserve of $9,405 and $18,502 for the three months ended March 31, 2024 and 2023, respectively.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

Office furniture			5 years
Electronic equipment			2-3 years
Machinery			3 years
Leasehold improvements			3 years
Vehicles			5 years

Impairment of Long-Lived Assets

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

Recoverability of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of March 31, 2024 and December 31, 2023, there were no significant impairments of its long-lived assets.

Goodwill

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions. The Company recorded goodwill in the amount of $0 as of March 31, 2024 and December 31, 2023.

Income Taxes

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

The Company follows Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

Under ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

At March 31, 2024 and December 31, 2023, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

Revenue Recognition

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

	●	executed contract(s) with customers that the Company believes is legally enforceable;

	●	identification of performance obligation in the respective contract;

	●	determination of the transaction price for each performance obligation in the respective contract;

	●	allocation of the transaction price to each performance obligation; and

	●	recognition of revenue only when the Company satisfies each performance obligation.

The Company’s revenue recognition policies for its various operating segments are as follows:

Products

The Company’s revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists. The Company does not provide unconditional return or other concessions to the customer. The Company’s sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to the product return option, the customers have the option of asking for an exchange for products with the same value.

Sales revenue of AiXin Zhonghong represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 13% since April 1, 2019. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

Hotel

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservation. Each of these products and services represents a distinct performance obligation and, in exchange for these services, the Company receives fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China.

Pharmacies

The Company’s retail drugstores (Aixintang Pharmacies) recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. Aixintang Pharmacies generally receives payments from customers as it satisfies its performance obligations. The Company records a receivable when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. Aixintang Pharmacies’ products sold in China are subject to the PRC VAT of 0%-13% as certain pharmacies qualify as small businesses.

Manufacture and Sale

The Company’s subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation. The Company records a receivable for its sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of Runcangsheng’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

Unearned Revenue

The Company’s unearned revenue primarily consists of advances received from customers for the purchase of products prior to the delivery of goods, and for the rental of hotel rooms prior to the delivery of service. The delivery of products and room rental services is based upon contract terms and customer demand, normally within one year.

Concentration of Credit Risk

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. As of March 31, 2024 and December 31, 2023, the Company has uninsured deposits in banks of $133,279 and $289,059 held in the PRC.

The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

During the three months ended March 31, 2024 and 2023, the Company had no customer that accounted for over 10% of its total revenue.

During the three months ended March 31, 2024, the Company had one major supplier that accounted for over 10% of its total purchases.

Supplier		Net purchases for the three months ended March 31, 2024				% of total purchase
A		$	44,920				12	%

During the three months ended March 31, 2023, the Company had two major suppliers that accounted for over 10% of its total purchases.

Supplier	Net purchases for the three months ended March 31, 2023		% of total purchase
B	$	68,717		17	%
C		61,737		15	%

Leases

The Company determines if an arrangement is a lease at inception under FASB ASC Topic 842, Right of Use Assets (“ROU”) and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of its leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. ROU assets are adjusted for prepayments and accrued lease payments. ROU assets also reflect any lease payments made prior to commencement and are recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease and such options are considered when determining the value of an ROU asset when it is reasonably certain that the Company will exercise such options.

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets.

ROU assets are tested for impairment individually or as part of an asset group if the cash flows related to the ROU asset are not independent from the cash flows of other assets and liabilities. An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The Company recognized no impairment of ROU assets as of March 31, 2024 and December 31, 2023. Operating leases are included in operating lease ROU and operating lease liabilities (current and non-current), on the consolidated balance sheets.

Statement of Cash Flows

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

Fair Value of Financial Instruments

The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the consolidated balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

Fair Value Measurements and Disclosures

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined as follow:

	●	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

As of March 31, 2024 and December 31, 2023, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

Foreign Currency Translation and Comprehensive Income (Loss)

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive income (loss) for the three months ended March 31, 2024 and 2023 consisted of net income (loss) and foreign currency translation adjustments.

Earnings per Share

Basic income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

As of March 31, 2024 and December 31, 2023, the Company did not have any potentially dilutive instruments.

Stock-Based Compensation

The Company periodically grants stock options, warrants and awards to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option, stock warrant and stock award grants to employees based on the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option, stock warrant and stock award grants to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the employees and non-employees, option, warrant and award grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

Segment Reporting

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

The Company manages its business as four operating segments, products, pharmacies, hotel, and manufacture and sales, all of which are located in the PRC. All of its revenues are derived in the PRC. All long-lived assets are located in PRC.

The following table shows the Company’s operations by business segment for the three months ended March 31, 2024 and 2023.

SCHEDULE OF SEGMENTS INFORMATION

	2024			2023
	For the Three Months Ended March 31,
	2024			2023
Net revenue
Products	$	165,749		$	163,260
Pharmacies		241,118			223,516
Hotel		154,465			332,417
Manufacture and sale		290,227			35,520
Total revenues, net	$	851,559		$	754,713

Operating costs and expenses
Products
Cost of goods sold	$	19,708		$	34,734
Operating expenses		372,056			367,789
Pharmacies
Cost of goods sold		80,174			138,633
Operating expenses		110,870			188,996
Hotel
Hotel operating costs		461,079			477,794
Operating expenses		71,877			(8,885	)
Manufacture and sale
Cost of goods sold		227,929			2,121
Operating expenses		129,112			105,501
Total operating costs and expenses	$	1,472,805		$	1,306,683

Loss from operations
Products	$	(226,015	)	$	(239,263	)
Pharmacies		50,074			(104,113	)
Hotel		(378,491	)		(136,492	)
Manufacture and sale		(66,814	)		(72,102	)
Loss from operations	$	(621,246	)	$	(551,970	)

Segment assets	As of March 31, 2024		As of December 31, 2023
Products	$	268,081	$	270,932
Pharmacies		544,702		425,546
Hotel		2,270,083		1,654,165
Manufacture and sale		2,376,188		2,491,715
Total assets	$	5,459,054	$	4,842,358

New Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 will be effective for annual reporting periods beginning after December 15, 2023, and interim periods within annual reporting periods beginning after December 15, 2024. Early adoption is permitted. The adoption of ASU 2023-01 did not have a material impact on the Company’s consolidated financial statement presentation or disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires disclosures of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. This ASU will be effective for annual reporting periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 will be applied on a prospective basis with the option to apply the standard retrospectively. The Company’s management does not believe that the adoption of ASU 2023-09 will have a material impact on the Company’s consolidated financial statement presentation or disclosures.

The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

3. OTHER RECEIVABLES AND PREPAID EXPENSES

Other receivables and prepaid expenses consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Deposits	$	40,383	$	8,978
Prepaid expenses, including related party (see Note 13)		106,413		128,378
Employees’ social insurance		9,447		8,667
Others		31,728		24,808
Total	$	187,971	$	170,831

4. ADVANCES TO SUPPLIERS

The Company had advances to suppliers of $225,294 and $152,563 as of March 31, 2024 and December 31, 2023, respectively. Advances to suppliers primarily include prepayments for products and equipment expected to be delivered subsequent to balance sheet dates.

5. INVENTORIES

Inventories consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INVENTORIES

	March 31, 2024		December 31, 2023
Raw material	$	110,218	$	114,005
Finished goods-health supplements		2,875		-
Drugs, pharmaceutical and nutritional products		358,387		324,588
Food and beverage, hotel supplies and consumables		75,439		81,969
Total	$	546,919	$	520,562
Less: reserve for inventory		87,503		79,464
Total inventories, net	$	459,416	$	441,098

6. PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Vehicles	$	443,854		$	451,381
Office furniture		80,434			80,612
Electronic equipment		25,493			25,899
Machinery		1,292,976			1,314,902
Leasehold improvements		1,110,548			1,125,581
Other		11,796			11,997
Total		2,965,101			3,010,372
Less: Accumulated depreciation		(1,413,890	)		(1,330,697	)
Property and equipment, net	$	1,551,211		$	1,679,675

Depreciation expense for the three months ended March 31, 2024 and 2023 was $105,842 and $104,400, respectively.

7. INTANGIBLE ASSET, NET

Intangible asset consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INTANGIBLE ASSET

	March 31, 2024			December 31, 2023
Software	$	12,309		$	12,516
Less: Accumulated amortization		(8,911	)		(8,599	)
Intangible asset, net	$	3,398		$	3,917

Amortization expense for the three months ended March 31, 2024 and 2023 was $457 and $161, respectively.

8. TAXES PAYABLE

Taxes payable consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF TAX PAYABLE

	March 31, 2024		December 31, 2023
Value-added	$	37,746	$	6,439
Income		29,498		29,998
City construction		2,520		1,423
Education		1,828		1,024
Other		9,516		10,365
Taxes payable	$	81,108	$	49,249

9. ACCRUED LIABILITIES AND OTHER PAYABLES

Accrued liabilities and other payables consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Accrued employees’ social insurance	$	214,820	$	231,983
Accrued payroll and commission		434,773		308,768
Accrued rent expense		3,980		-
Construction payable		1,200,585		1,229,775
Payable for equipment purchase		22,718		30,307
Accrued professional fees		298,570		250,505
Deposit		10,802		10,986
Other payables		63,184		100,742
Total	$	2,249,432	$	2,163,066

10. GOVERNMENT GRANT

On December 1, 2021, The Company and Luquan Yizu Miaozu Autonomous County People’s Government (“the People’s Government”) entered a cooperation agreement with a term of 10 years. According to the agreement, the People’s Government will contribute RMB 8,000,000 ($1,194,400) as a one-time payment to the Company for deep processing of Chinese herbs. The Company can retain the contributed amount at the end of the cooperation term if it passes the performance assessment by People’s Government; otherwise, it will return the full proceeds received plus a 20% penalty. As of March 31, 2024 and December 31, 2023, the Company received $907,843 and $923,238 from the People’s Government, the Company plans to return the funds to the People’s Government as it is not the full amount the Peoples’ Government promised to contribute.

11. LOAN FROM THIRD PARTIES

As of March 31, 2024 and December 31, 2023, the Company had advances from unrelated third parties of Aixin Shangyan Hotel in an aggregate amount $83,099 and $84,508, respectively. There was no written agreement, and these loans are payable on demand and bear no interest.

12. LEASE

AiXinZhonghong leases its office. The lease has a remaining lease term of approximately 4.16 years.

Aixin Shangyan Hotel leases its hotel premises under an operating lease arrangement. The leases have remaining lease terms of approximately 1 to 10 years.

Aixintang Pharmacies lease retail pharmacy stores under operating lease arrangements, with remaining lease terms of 0.71 to 2.42 years.

Runcangsheng leases its office under an operating lease arrangement. The lease was expired as of December 31, 2023. In January 2024, the lease was renewed with an expiration date of December 31, 2024.

Balance sheet information related to the Company’s leases is presented below:

SCHEDULE OF OPERATING LEASE LIABILITIES

	March 31, 2024		December 31, 2023
Operating Leases
Operating lease right-of-use assets	$	2,125,320	$	1,576,814

Operating lease liabilities – current	$	208,842	$	864,519
Operating lease liability – non-current		1,901,857		789,489
Total operating lease liabilities	$	2,110,699	$	1,654,008

The following provides details of the Company’s lease expenses:

SCHEDULE OF OPERATING LEASE EXPENSES

	2024		2023
	Three Months Ended March 31,
	2024		2023
Operating lease expenses	$	233,070	$	210,334

Other information related to leases is presented below:

	Three Months Ended March 31,
	2024			2023
Cash Paid for Amounts Included In Measurement of Liabilities:
Operating cash flows from operating leases	$	325,498			186,473

Weighted Average Remaining Lease Term:
Operating leases		8.90 years			1.36 years

Weighted Average Discount Rate:
Operating leases		4.84	%		4.75	%

Maturities of lease liabilities were as follows:


For the year ending December 31:
2024 (excluding the three months ended March 31, 2024)	$	249,956
2025		328,117
2026		266,812
2027		229,907
2028		225,060
Thereafter		1,341,088
Total lease payments		2,640,940
Less: imputed interest		(530,241	)
Total lease liabilities		2,110,699
Less: current portion		(208,842	)
Lease liabilities – non-current portion	$	1,901,857

13. RELATED PARTY TRANSACTIONS

Accounts receivable – related party

Accounts receivable – related party consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	2,410	$	2,451
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		101,796		4,309
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		1,994		2,028
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		1,994		2,028
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		19,667		-
Xiaoyan Zhou		15,332		32,493
Chengdu Aixin International Travel Service Co., Ltd		41,519		43,083
Total	$	184,712	$	86,392

The related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). Xiaoyan Zhou is the wife of Huiliang Jiao, the Company’s Director.

Sales revenue – related party

Sales revenue – related party consisted of the following for the periods indicated:


	Three Months Ended March 31,
	2024		2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd	$	19,943	$	-
Chengdu Aixin International Travel Service Co., Ltd		6,443		24,055
Total	$	26,386	$	24,055

Prepaid expense – related party

Prepaid expense – related party consisted of the following as of the periods indicated:

		March 31, 2024				December 31, 2023
Chengdu Aixin International Travel Service Co., Ltd		$	90,731			$	120,483

Chengdu Aixin International Travel Service Co., Ltd is owned by the Company’s CEO.

Accounts payable – related party

Accounts payable – related party consisted of the following as of the periods indicated:

		March 31, 2024				December 31, 2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd.		$	-			$	1,776

Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd. is an entity controlled by Quanzhong Lin, CEO of the Company.

Due from related parties

Due from related parties consisted of the following as of the periods indicated:

SCHEDULE OF RELATED PARTY TRANSACTIONS

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	554	$	563
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		83		85
Chengdu Zhiweibing Pharmacy Co., Ltd.		1,709		1,738
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		692		704
Sichuan Aixin Investment Co. Ltd		9,155		9,310
Sichuan Yunxi Tang Pharmacy Co., Ltd		83		-
Chengdu Hesheng Yuan Pharmacy Co., Led		130		-
Huiliang Jiao		49,545		-
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		40,486		-
Total	$	102,437	$	12,400

Due to related parties

Due to related parties consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Quanzhong Lin	$	1,534,932	$	1,051,429
Yirong Shen		85,869		87,325
Huiliang Jiao		-		82,152
Tianfeng Li		-		780
Mianyang Aixin Cunshan Pharmacy Co. Ltd		110		112
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		53,275		-
Chengdu Aixin International travel service Co, Ltd		5,002		5,087
Total	$	1,679,188	$	1,226,885

The amounts due from related parties and due to related parties described above were for working capital purposes, payable on demand, and bear no interest. All the related party entities listed above are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). Yirong Shen was a major shareholder of Aixin Shangyan Hotel prior to the closing of Hotel Purchase Agreement, and she serves as the supervisor of Aixin Shangyan Hotel. Mr. Huiliang Jiao is a Director of the Company. Tianfeng Li is the CFO of Aixin Life.

Office leases

In May 2014, the Company entered a lease with its major shareholder for an office. The lease term was for three years expiring in May 2017 with an option to renew. The monthly rent was RMB 5,000 ($704). The Company was required to prepay each year’s annual rent at 15th of May of each year. The Company renewed the lease until May 28, 2028 with monthly rent of RMB 5,000 ($704), payable quarterly. The future annual minimum lease payments at March 31, 2024 are $6,260, $8,346, $8,346, $8,346, and $3,478 for each of the years ended December 31, 2024, 2025, 2026, 2027, and 2028, respectively.

Runcangsheng has an office lease with Xiaoyan Zhou, wife of Huiliang Jiao, the Company’s Director, from March 2020 to February 2023 with a monthly rent of RMB 3,000 ($414). Runcangsheng renewed the lease until February 28, 2026 with monthly rent of RMB 5,000 ($690). In July 2023, Xiaoyan Zhou entered into an agreement with Runcangsheng to increase the monthly rent for 2022 by RMB 2,000 and to change the lease expiration date to December 31, 2023. The lease will be converted to an annual contract starting from January 1, 2024.

14. INCOME TAXES

The Company was incorporated in the United States of America (“USA”) and has operations in one tax jurisdiction, i.e. the PRC. The Company generated substantially all of its sales from its operations in the PRC for the three months ended March 31, 2024 and 2023, and recorded income tax provision for the periods.

China has a tax rate of 25% for all enterprises (including foreign-invested enterprises).

Uncertain Tax Positions

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the three months ended March 31, 2024 and 2023, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

15. STOCKHOLDERS’ EQUITY

The Company is authorized to issue 20,000,000 shares of blank check preferred stock at $0.001 par value and 500,000,000 shares of common stock at $.00001 par value per share.

Pursuant to resolutions adopted by the Board of Directors and the holders of a majority of the outstanding shares of common stock of AiXin Life International, Inc. on January 6, 2023, the Company filed an amendment to its Articles of Incorporation with respect to a proposed 1 for 2 “reverse” split of its common stock (the “Amendment”). Completion of the proposed reverse stock split was to be effected on a date determined by the Board of Directors only upon receipt of notice from the Financial Industry Regulatory Authority (“FINRA”) that it would process the proposed reverse stock split. The Company received notice from FINRA and its common stock began trading on a post-split basis on February 17, 2023.

As a result of the reverse split, every two shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Company has approximately 24,999,834 shares of outstanding common stock after giving effect to the reverse stock split and the elimination of fractional shares.

All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

As of March 31, 2024 and December 31, 2023, the Company had 24,999,834 common shares issued and outstanding, after reverse stock split adjustment.

Stock Awards Issued for Services

On October 22, 2019, the Company granted and issued 18,750 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $337,500 based on the post-split closing price of $18 on the grant date.

On October 24, 2019, the Company granted and issued 275,000 shares to its employees and contractors under its 2019 Equity Incentive Plan. The stock awards were valued at $1,520,200 based on the post-split closing price of $5.528 on the grant date.

The stock awards will vest over five (5) years from the grant date, and the grantee will forfeit a portion of the shares granted (“Shares Granted”) if the grantee is no longer employed by or contracted with the Company. Specifically, the grantee will forfeit 80% of Shares Granted if no longer employed by or contracted with the Company on the date that is one year from the grant date, forfeit 60% of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from the grant date, forfeit 40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years from the grant date, and forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four years from the grant date. Effective on the 5^th year from the grant date, none of the shares will be subject to forfeiture.

For the three months ended March 31, 2024 and 2023, stock-based compensation expenses were $92,885 and $92,885, respectively. As of March 31, 2024, unrecognized compensation expenses related to these stock awards are $208,242. These expenses are expected to be recognized over 0.56 years.

Capital Contribution

During the year ended December 31, 2023, the Company received capital contributions in the aggregate amount of $145,300 from Yunnan Shengshengyuan and Yun Chen, the former shareholders of Runcangsheng (see Note 1), who remained as related parties of the Company after the completion of acquisition of Runcangsheng.

16. STATUTORY RESERVES

Pursuant to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

Surplus reserve fund

The Company is required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the three months ended March 31, 2024 and 2023, the Company made $0 and $0 contribution to statutory reserve fund.

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

Common welfare fund

Common welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations. The Company did not make any contribution to this fund during the three months ended March 31, 2024 and 2023.

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

17. OPERATING CONTINGENCIES

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.

Litigation

The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.

In October 2020, Jian Yiao (the “Plaintiff”) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (“Aixintang Pharmacy”, or the “Defendant”) in Zhangjiagang People’s Court in Jiangsu Province. The complaint alleges that Jian Yiao is entitled to $392,305 (RMB 2,500,000) from Aixintang Pharmacy for not fulfilling the contractual obligation of a purchase agreement entered in March 2020 (the “Purchase Agreement”). Aixintang Pharmacy claimed that the Purchase Agreement was falsely entered by an employee through forged documents, and that Aixintang Pharmacy did not enter the Purchase Agreement. The Court determined that Aixintang Pharmacy breached the Purchase Agreement by not delivering the products ordered and ordered Aixintang Pharmacy to pay $392,305 (RMB 2,500,000) to the Plaintiff. In December 2020, Aixintang Pharmacy filed a motion of appeal in the Jiangsu Suzhou Intermediate People’s Court against the determination reached from the first trial.

In February 2021, the judge in the Jiangsu Suzhou Intermediate People’s Court denied the Defendant’s motion and upheld the judgment from the first trial. In March 2021, Aixintang Pharmacy filed another motion of re-trial to the Jiangsu High People’s Court on the basis that the Purchase Agreement was forged, the motion was accepted by Jiangsu High People’s Court in July 2021. In September 2022, the Court rejected the Defendant’s motion and upheld the judgment rendered in the second trial.

In April 2021, Jian Yiao applied for the first execution of the judgement; a total of $97,748 (RMB 694,000) was received. On June 13, 2023, Jian Yiao applied to execute for the balance. The total amount executed this time was $110,818 (RMB 786,800), and the remaining amount including overdue interest of $139,692 (RMB 991,800) was not executed. To date, the amount that was frozen from this case was $44,292 (RMB 319,805), the total amount executed was $212,412 (RMB 1.51 million), and the bank accounts of Chengdu Aixin Tang Haichuan Pharmacy Co., Ltd and its three branches were still frozen as of this report date.

In November 2021, the Company and Mr. Quanzhong Lin agreed that Mr. Lin shall assume any losses arising from this legal proceeding. As such, the Company did not accrue contingent losses from this legal proceeding as of March 31, 2024.

The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.

18. SUBSEQUENT EVENT

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company has no material subsequent events.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes to those statements included elsewhere in this Form 10-Q and with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”). This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in our 2023 Form 10-K, that could cause actual results to differ materially from those anticipated in these forward-looking statements.

Overview

In December 2017, we completed a “reverse” acquisition whereby we acquired all of the outstanding shares of AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”). As a result, AiXin BVI became our wholly-owned subsidiary, and through AiXin BVI we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXinZhongHong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhongHong”), which began distributing nutritional products in 2013.

In September 2021, we completed the acquisition of nine pharmacies located in Chengdu by acquiring the entities which owned the pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5.31 million. We currently operate at 26 locations, including 18 locations operated pursuant to a single chain license.

Pursuant to an Equity Transfer Agreement (the “Transfer Agreement”), on September 30, 2022, we acquired all of the outstanding equity of Yunnan Runcangsheng Technology Co., Ltd (“Runcangsheng”) for RMB 31,557,820 (approximately USD$4.4 million), reduced by $116,802 the excess of the estimated net worth of Runcangsheng over its audited net worth as of December 31, 2021. In addition to transferring their respective equity interest in Runcangsheng, both Sellers agreed to forgive any loans due to them from Runcangsheng. Runcangsheng. was established in April 2020, and is headquartered in Luquan Yi and Miao Autonomous County, Kunming City, Yunnan Province.

Runcangsheng operates a 13,000 square meter production facility, which houses R&D centers, extraction facilities, preparation workshops and a warehouse. Runcangsheng has more than 30 sub brands and is focused on promoting a healthy lifestyle through the use of foods believed to promote well-being, health foods, modernized versions of traditional Chinese medical products and plant extracts. Runcangsheng cultivates many of the raw materials used in its products, compounds the materials into easy to transport and use pre-packaged foods and distributes the products at the wholesale level. As life-styles in China evolve, work pressures increase and the ingestion of meats and other western style foods increases, Runcangsheng seeks to design and market products intended to combat the increase in obesity, hypertension, insomnia and physical ailments associated with such changes. The acquisition of Runcangsheng will enable us to operate as a vertically integrated company, capable of formulating the kinds of health foods and other nutritional products and supplements suitable for our clients and marketing those products through our distribution channels.

In addition to our acquisitions in the health and nutritional sector, in July 2021, we completed the acquisition of Aixin Shangyan Hotel through which we owned and operated a hotel located in the Jinniu District, Chengdu City. Effective March 31, 2024, we terminated our lease for the Shangyan Hotel. In the termination agreement we and the landlord agreed to release each other from any claims and the landlord agreed to return the security deposit.

On February 6, 2024, we entered into a lease with respect to a hotel located in Bandzhuyuan Town, Xindu District, Chengdu City. The term of the lease commenced February 29, 2024 and expires April 15, 2034. The Lease grants us the right to occupy various areas within the hotel, covering approximately 18,000 square meters, including the first-floor lobby, external shops (subject to the rights of the current occupants), the second and third floors, portions of the fourth floor including the restaurant and tea shop, and the fifth through eighteenth floors comprised mainly of guest rooms, underground and ground parking lots, and all hotel facilities and equipment. References to hotel revenues and operating costs below are with respect to the hotel we previously occupied in the Jinniu District of Chengdu.

We intend to look for additional opportunities to profit from the growing healthcare market in China. Though currently we are not party to any agreements, we will explore, among other opportunities, expanding our product line through internal research and acquiring complementary products from third parties, acquiring additional pharmacies and other retail outlets and operating nursing homes and possibly clinics which provide medical care to clients.

Our Business

We are focused on providing health and wellness products to the growing middle class in China. We currently develop, manufacture, market and sell premium-quality healthcare, nutritional products and wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such as weight management tools, probiotics, foods and drinks. We offer products manufactured by us and those purchased from third parties through a diversified, omni-channel business model which generates revenues through retail and wholesale product sales, through company-owned pharmacies, direct marketing and e-commerce. Our marketing approach emphasizes proactively approaching customers such as by hosting marketing events for clients, which we believe is ideally suited to marketing the products we offer because sales of healthcare, nutritional products and supplements are strengthened by ongoing personal contact and support, coaching and education among the Company and our clients towards how to achieve a healthy and active lifestyle.

We believe the competitive strengths that will enable us to grow in the health and wellness market include our ability to design and manufacture products that are responsive to consumers’ needs as the life style of China’s middle class evolves, our coordinated omni-channel distribution network where we enable consumers to obtain the information they need to improve their lifestyle on our website, at our pharmacies and through individual meetings with our team members.

Our ability to operate profitably and generate positive cash flow will be determined by our ability to attract a large and loyal customer base and provide the information and products they need cost effectively. Our revenue will largely be determined by our ability to achieve and maintain a strong brand name and company image, the volume of products we sell and the prices we can charge for such products, which will require that we compete effectively. Our costs will largely be determined by the cost of raw materials and acquired inventory, the labor used to design and manufacture products, and the costs incurred to deliver these products to the consumer.

We intend to build a reputation as a provider of premium health and wellness products that seeks to improve our customers health and well-being. Our objective is to offer a broad and deep mix of products for consumers interested in living well, whether they are looking to treat a health-related issue or simply maintain their overall wellness. Our premium, value-added offerings include both proprietary products developed and manufactured by us as well as products acquired from or sold on behalf of third parties. We believe our range of products and ability to develop new products, combined with the customer support and service we offer, differentiate us and allow us to effectively compete against food, drug and mass channel players, specialty stores, independent vitamin, supplement and natural food shops and online retailers. There is no assurance that we will achieve our business objectives.

Results of Operations

Three Months ended March 31, 2024 and 2023

The following table sets forth the results of our operations for the periods indicated as a percentage of net revenue. Certain columns may not add due to rounding:

	Three Months Ended March 31,
	2024						2023
	$			*% of* *Revenue*			$			*% of* *Revenue*
Revenue	$	851,559			100	%	$	754,713			100	%
Operating costs and expenses		1,472,805			173	%		1,306,683			173	%
Loss from operations		(621,246	)		(73	)%		(551,970	)		(73	)%
Non-operating income, net		17,646			2	%		22,643			3	%
Loss before income tax		(603,600	)		(71	)%		(529,327	)		(70	)%
Income tax expense		-			-	%		457			-	%
Net loss	$	(603,600	)		(71	)%	$	(529,784	)		(70	)%

The following table shows our operations by business segment for the three months ended March 31, 2024 and 2023.

	For the Three Months Ended March 31,
	2024			2023
Net revenue
Products	$	165,749		$	163,260
Pharmacies		241,118			223,516
Hotel		154,465			332,417
Manufacture and sale		290,227			35,520
Total revenues, net	$	851,559		$	754,713

Operating costs and expenses
Products
Cost of goods sold	$	19,708		$	34,734
Operating expenses		372,056			367,789
Pharmacies
Cost of goods sold		80,174			138,633
Operating expenses		110,870			188,996
Hotel
Hotel operating costs		461,079			477,794
Operating expenses		71,877			(8,885	)
Manufacture and sale
Cost of goods sold		227,929			2,121
Operating expenses		129,112			105,501
Total operating costs and expenses	$	1,472,805		$	1,306,683

Loss from operations
Products	$	(226,015	)	$	(239,263	)
Pharmacies		50,074			(104,113	)
Hotel		(378,491	)		(136,492	)
Manufacture and sale		(66,814	)		(72,102	)
Loss from operations	$	(621,246	)	$	(551,970	)

Revenue

Revenue was $851,559 in the three months ending March 31, 2024, compared to $754,713 in the same period of 2023, an increase of $96,846 or 13%. The increase in revenue was mainly due to increases in direct sales of our nutritional products, pharmacies’ sales, and increases in revenue from Runcangsheng, which was partly offset by a decrease in revenues from our hotel sector. For the three months ended March 31, 2024, we had $697,094 in product revenues (of which $165,749 were from direct sales, $241,118 were from sales at our pharmacies and $290,227 from sales by Runcangsheng) and hotel revenue of $154,465. For the three months ended March 31, 2023, we had $422,296 in product revenues (of which $163,260 were from direct sales, $223,516 were from sales at our pharmacies and $35,520 from sales by Runcangsheng) and hotel revenue of $332,417.

Direct products sales

Our direct products sales revenue was $165,749 for the three months ended March 31, 2024, compared with $163,260 in the same period of 2023, representing an increase of $2,489 or 2%. Our direct products sales revenue as a percentage to total revenue was 19% for the three months ended March 31, 2024, compared to 22% for the same period of 2023.

Pharmacies Revenue

Our pharmacies revenue was $241,118 for the three months ended March 31, 2024, compared with $223,516 in the same period of 2023, representing an increase of $17,602 or 8%. Our pharmacies revenue as a percentage to total revenue was 28% for the three months ended March 31, 2024, compared to 30% for the same period of 2023. The increase in pharmacies revenue was a result of our chain stores joint promotion activities which allowed customers able to purchase the products that are not sold in their regular stores but available in our other chain stores, as well as increased demand from our members for the health supplement products.

Hotel Revenue

Our hotel revenue was $154,465 for the three months ended March 31, 2024, compared with $332,417 for the same period of 2023, representing a decrease of $177,952 or 54%. Our hotel revenue as a percentage of total revenue was 18% for the three months ended March 31, 2024, compared to 44% for the same period of 2023. The Chinese New Year occurred in the first quarter of 2024 andpersonnel associated with Zhonghong and long-term customers held meetings and celebratory events in the hotel which reduced the number of external guests, which resulted a decrease in revenue.

Manufacture and sales

Our manufacture and sales revenues were $290,227 for the three months ended March 31, 2024, compared with $35,520 for the same period of 2023, representing an increase of $254,707 or 717%. Our manufacture and sales revenue as a percentage of total revenue was 34% for the three months ended March 31, 2024, compared to 5% for the same period of 2023. The increase in manufacture and sales was mainly driven by the addition of new salespeople and increased consumer demand during the Chinese New Year.

Operating Costs and Expenses

Cost of Goods Sold

Cost of goods sold was $327,811 for the three months ended March 31, 2024, compared to $175,488 for the same period of 2023, an increase of $152,323 or 87%. The increase in cost of goods sold was attributable to the increase in Runcangsheng’s manufacture and sales business.

Direct products sales

The cost of goods sold for our direct products was $19,708 for the three months ended March 31, 2024, compared with $34,734 for the same period of 2023, representing a decrease of $15,026 or 43%. The cost of goods sold for our direct product sales as a percentage of sales was 12% for the three months ended March 31, 2024, compared to 21% for the same period of 2023. The decrease in cost of goods sold was primarily driven by the elimination of a commission program for our sales personnel in the first quarter of 2024.

Pharmacies Revenue

The cost of goods sold at our pharmacies was $80,174 for the three months ended March 31, 2024, compared with $138,633 for the same period of 2023, representing a decrease of $58,459 or 42%. The cost of goods sold at our pharmacies as a percentage of pharmacy product sales was 33% for the three months ended March 31, 2024, compared to 62% for the same period of 2023. The decrease in cost of goods sold was mainly due to our coordination of activities at our pharmacies, such as the implementation of bulk inventory purchasing which reduced our purchasing costs; and cost reduction measures undertaken in September 2023, including reviewing our list of vendors and replacing those vendors with higher cost products.

Manufacture and sales

The cost of goods sold for our manufacture and sales was $227,929 for the three months ended March 31, 2024, compared with $2,121 for the same period of 2023, representing an increase of $225,808 or 10,646%. The cost of goods sold as a percentage of sales by our manufacture and sales was 79% for the three months ended March 31, 2024, compared to 6% for the same period of 2023. The primary reason for the increase in cost of goods sold was due to the significant increase of sales.

Hotel Operating Costs

Hotel operating costs were $461,079 and $477,794 for the three months ended March 31, 2024 and 2023, respectively, representing a decrease of $16,715 or 3%. For the three months ended March 31, 2024, our hotel revenue significantly decreased compared to the same period in 2023. However, due to the fixed operating costs, our overall expenses did not decrease substantially.

Operating Expenses

Operating expenses were $683,915 for the three months ended March 31, 2024, compared to $653,401 for the same period of 2023, an increase of $30,514 or 5%. The increase in operating expenses was mainly due to the increase in operating expenses reported from the hotel and Runcangsheng sectors, which was partly offset by decreased operating expenses at our pharmacies.

Loss from Operations

Loss from operations was $621,246 in the three months ended March 31, 2024, compared to $551,970 in the same period of 2023, an increase of $69,276 or 13%. The increase in our loss from operations for the first quarter of 2024 was primarily due to the increase in the loss at or hotel of approximately $242,000, partially offset by decreases in the operating loss at each of our other segments. Notably, our pharmacies generated a profit from operations in the first quarter of 2024.

Non-operating Income

Non-operating income was $17,646 for the three months ended March 31, 2024, compared to $22,643 for the three months ended March 31, 2023. For the three months ended March 31, 2024, we had interest income of $114 and other income of $18,802, partly offset by other expenses of $1,270. For the three months ended March 31, 2023, we had interest income of $289 and other income of $24,861, partly offset by other expenses of $2,507.

Income Tax Expense

Income tax expense was $nil and $457 for the three months ended March 31, 2024 and 2023, respectively, a decrease of $457 or 100% for the three months ended March 31, 2024 compared with the same period of 2023.

Net Loss

Our net loss for the three months ended March 31, 2024 was $603,600, compared to a net loss of $529,784 for the same period of 2023, an increase of $73,816 or 14%. The increase in our net loss was mainly due to increased operating costs and expenses, partly offset by increased sales as explained above, particularly at our hotel where the operating loss increased by nearly $242,000.

Liquidity and Capital Resources

During the three months ended March 31, 2024, we used $461,451 in operations. As of March 31, 2024, cash and cash equivalents were $305,027 (excluding $35,967 of restricted cash), compared to $443,758 (excluding $23,208 of restricted cash) as of December 31, 2023. At March 31, 2024, we had a working capital deficit of $4,250,016 compared to $4,467,006 at December 31, 2023.

The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2024 and 2023, respectively.

	March 31, 2024			March 31, 2023
Net cash used in operating activities	$	(461,451	)	$	(472,681	)
Net cash used in investing activities	$	(41,053	)	$	(5,181	)
Net cash provided by financing activities	$	383,802		$	437,560

Net cash used in operating activities

For the three months ended March 31, 2024, net cash used in operating activities was $461,451. This reflects our net loss of $603,600, adjusted by non-cash related expenses including depreciation and amortization expense of $106,299, a bad debt expense of $8,027, an inventory impairment of $9,405, operating lease expenses of $233,070 and stock-based compensation of $92,885, and then decreased by changes in working capital of $307,537. The cash outflow from changes in working capital mainly resulted from increases in other receivables and prepaid expense of $20,080, an increase in accounts receivable of $38,491, an increase in related party receivables of $100,603, an increase in advance to suppliers of $39,498, an increase in inventory of $35,192, and payments of lease liabilities of $325,498, partly offset by cash inflows from accrued liabilities and other payables of $124,299, from taxes payable of $32,823, from accounts payable (net of accounts payable to related parties) of $15,774, and from unearned revenue of $78,999.

For the three months ended March 31, 2023, net cash used in operating activities was $472,681. This reflects our net loss of $529,784, adjusted by non-cash related expenses including depreciation and amortization expense of $104,561, change in deferred tax of $457, bad debt reversal of $43,816, inventory impairment of $18,502, operating lease expense of $210,334 and stock-based compensation of $92,885, and then decreased by changes in working capital of $325,820. The cash outflow from changes in working capital mainly resulted from increases in other receivables and prepaid expense of $50,416, in inventory of $200,787, in accounts payable from related party of $167,209, and in accrued liabilities and other payable of $123,208, and payments of lease liabilities of $186,473, partly offset by cash inflow from accounts receivable of $176,944, cash inflow from advances to suppliers of $49,587, cash inflow from accounts payable of $42,332 and unearned revenue of $192,689.

Net cash used in investing activities

For the three months ended March 31, 2024 and 2023, net cash used in investing activities was $41,053 and $5,181, respectively. For the three months ended March 31, 2024, net cash used in investing activities including $41,053 for the purchase of fixed assets. For the three months ended March 31, 2023, net cash used in investing activities included $1,746 for purchase of fixed assets, and $3,435 cash disposed at the termination of a subsidiary due to non-operation.

Net cash provided by financing activities

For the three months ended March 31, 2024, net cash provided by financing activities was the result of proceeds from advances from related parties of $383,802. For the three months ended March 31, 2023, net cash provided by financing activities were the result of advances from related parties of $437,560.

We generated a $603,600 loss for the three months ended March 31, 2024. It is likely that Runcangsheng will require additional capital to achieve its short term operational goals and long range business plans. Further, we may need additional capital to maintain our other businesses. We may also have to raise additional financing as our working capital requirements are expected to increase in line with the growth of our business. In the past we have funded our operations through proceeds from private placements of equity and advances from our principal shareholder. Should we require capital to fund our business, we intend to finance our business by raising additional capital or, when available, borrowing additional funds. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders and could cause the price of our common stock to decrease. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

We are subject to all of the substantial risks inherent in the development of a new business enterprise within an extremely competitive industry. Due to the absence of a long-standing operating history and the emerging nature of the markets in which we compete, we anticipate operating losses until we can successfully implement our business strategy. Our revenue model is new and evolving, and we cannot be certain that it will be successful. The potential profitability of our business model is unproven. We may never achieve profitable operations. Our future operating results depend on many factors, including demand for our products, the level of competition, and the ability of our officers to manage our business and growth. As a result of the emerging nature of the market in which we compete, we may incur operating losses until such time as we can develop a substantial and stable revenue base. Additional development expenses may delay or negatively impact our ability to generate profits. Accordingly, we cannot assure you that our business model will be successful or that we can sustain revenue growth, achieve or sustain profitability, or continue as a going concern.

Our ability to obtain funds through the issuance of debt or equity is dependent upon the state of the financial markets at such time as we may seek to raise funds. The state of the capital market markets may be adversely impacted by various risks and uncertainties, including, but not limited to future and current impacts of global events such as COVID-19, the war in the Ukraine and the conflict in Palestine, increases in inflation and other risks detailed herein.

Impact of Inflation

Our results of operations may be affected by inflation, particularly rising prices for products and other operating costs if we cannot pass such increases along to our customers in the form of higher prices for our products and services. Generally, we are not party to long term contracts and our inventory turns multiple times per year and we anticipate that we will be able to increase prices on products to reflect increases in the cost of inventory.

Contractual Obligations

We have no long-term fixed contractual obligations or commitments other than leases that are disclosed in Note 12 in the notes to our consolidated financial statements.

Contingencies

Our operations are conducted in the PRC and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments in China and foreign currency exchange rates. Our results may be adversely affected by changes in PRC government policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad and rates and methods of taxation, among other things.

Our sales, purchases and expense transactions in China are denominated in RMB and all of our assets and liabilities in China are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current PRC law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation in order to affect the remittance.

Significant Accounting Policies

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

Basis of Presentation

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhongHong, Aixin Shangyan Hotel, Aixintang Pharmacies, and Runcangsheng is the Chinese Renminbi (“RMB”). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

Use of Estimates

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

Accounts Receivable

We maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of March 31, 2024 and December 31, 2023, the bad debt allowance was $87,287 and $80,640, respectively.

Revenue Recognition

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of our products and services to customers in return for expected consideration and includes the following elements:

	●	executed contract(s) with customers that we believe are legally enforceable;

	●	identification of performance obligation in the respective contract;

	●	determination of the transaction price for each performance obligation in the respective contract;

	●	allocation of the transaction price to each performance obligation; and

	●	recognition of revenue only when we satisfy each performance obligation.

Our revenue recognition policies for our operating segments are as follows:

Products

Our revenue from sales of products is recognized when goods are delivered to the customer and no other obligation exists. We do not provide unconditional return or other concessions to customers. Our sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As an alternative to returning a product, customers may request an exchange for products with the same value.

Product sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of our products sold in China are subject to the PRC VAT of 13% of the gross sales price since April 1, 2019. This VAT may be offset by VAT paid by for raw materials and other materials purchased in China. We record VAT payables and VAT receivables net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as we act as an agent for the government.

Pharmacies

Our retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation. We generally receive payment from pharmacy customers we satisfy our performance obligations. We record a receivable when we have an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. The products sold in our pharmacies are subject to the VAT of 0%-13% as certain pharmacies qualify for small business exemption.

Manufacture and Sale

The Company’s subsidiary Runcangsheng recognizes revenue at the time products are shipped as this satisfies its performance obligation. The Company records a receivable for the sales when it has an unconditional right to receive payment and only the passage of time is required before payment is due. Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products sold in China are subject to the PRC VAT of 13% unless it is a qualified small business subject to exemption.

Hotel

Hotel revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservations. Each of these products and services represents a distinct performance obligation and, in exchange for these services, we receive fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied. All of the hotel’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by on raw materials and other materials purchased in China.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Management of AiXin Life International, Inc. is responsible for maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

At March 31, 2024, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Exchange Act was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based on their evaluation of our disclosure controls and procedures, they concluded that at March 31, 2024, such disclosure controls and procedures were not effective. This was due to our limited resources, including the absence of a financial staff with accounting and financial expertise and deficiencies in the design or operation of our internal control over financial reporting that adversely affected our disclosure controls and that may be considered to be “material weaknesses.”

We plan to designate individuals responsible for identifying reportable developments and to implement procedures designed to remediate the material weakness by focusing additional attention and resources in our internal accounting functions. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

There is no pending litigation to which we are presently a party or to which our property is subject which is likely to have a material impact on our financial condition and management is not aware of any facts which are likely to result in such a litigation in the future.

Item 1A. Risk Factors

Reference is made to the risks and uncertainties disclosed in Item 1A (“Risk Factors”) of our 2023 Form 10-K, which are incorporated by reference into this report. Prospective investors are encouraged to consider the risks described in the 2023 Form 10-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended March 31, 2024, we did not have any sales of equity securities in transactions that were not registered under the Securities Act of 1933, as amended, that have not been previously reported in a report filed pursuant to the Exchange Act.

Item 3. Defaults Upon Senior Securities

None.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit No.		Description

3.1		Articles of Incorporation (incorporated by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2006 as filed with the SEC on March 7, 2007).

3.2		Articles of Amendment to Articles of Incorporation (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).

3.3		Articles of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.3 the Company’s Quarterly Report on Form 10-Q for the quarterly period ended November 30, 2017 as filed with the SEC on January 16, 2019).

3.4		Bylaws of the Registrant (incorporated by reference to Exhibit 3.6 to Amendment to Form S-1 filed with the SEC on January 17, 2023).

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14 or Rule 15d-14 of Securities Exchange Act of 1934.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14 or Rule 15d-14 of Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).

32.2		Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).

101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation
101.DEF		Inline XBRL Taxonomy Extension Definition
101.LAB		Inline XBRL Taxonomy Extension Label
101.PRE		Inline XBRL Taxonomy Extension Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AIXIN LIFE INTERNATIONAL, INC.

Dated: June 13, 2024	By:	/s/ Quanzhong Lin
		Quanzhong Lin
		President and Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE EXCHANGE ACT

I, Quanzhong Lin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AiXin Life International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: June 13, 2024

/s/ Quanzhong Lin
Quanzhong Lin
Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) UNDER THE EXCHANGE ACT

I, Tianfeng Li, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AiXin Life International, Inc.

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: June 13, 2024

/s/ Tianfeng Li
Tianfeng Li
Chief Financial Officer (Principal Financial Officer)

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of AiXin Life International, Inc., a Colorado corporation (the “Company”), on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”) Quanzhong Lin, Chief Executive Officer of the Company, does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. ss. 1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: June 13, 2024

/s/ Quanzhong Lin
Quanzhong Lin
Chief Executive Officer (Principal Executive Officer)

[A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.]

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of AiXin Life International, Inc., a Colorado corporation (the “Company”), on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), Tianfeng Li, Chief Financial Officer of the Company, does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. ss. 1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: June 13, 2024

/s/ Tianfeng Li
Chief Financial Officer (Principal Financial Officer)

[A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company. and furnished to the Securities and Exchange Commission or its staff upon request.]

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 26, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	0-17284
Entity Registrant Name	AIXIN LIFE INTERNATIONAL, INC.
Entity Central Index Key	0000835662
Entity Tax Identification Number	84-1085935
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Hongxing International Business Building 2, 14th FL
Entity Address, Address Line Two	No. 69 Qingyun South Ave.,
Entity Address, Address Line Three	Jinjiang District
Entity Address, City or Town	Chengdu City
Entity Address, Country	CN
City Area Code	86
Local Phone Number	313-6732526
Title of 12(b) Security	Common Stock, $0.00001 Par Value
Trading Symbol	AIXN
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,999,842

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 305,027	$ 443,758
Restricted cash	35,967	23,208
Accounts receivable, including related parties, net	379,845	253,586
Other receivables and prepaid expenses, including related party	187,971	170,831
Advances to suppliers	225,294	152,563
Inventory, net	459,416	441,098
Due from related parties	102,437	12,400
Total current assets	1,695,957	1,497,444
Property and equipment, net	1,551,211	1,679,675
Intangible assets, net	3,398	3,917
Security deposit	83,168	84,508
Operating lease right-of-use assets	2,125,320	1,576,814
Goodwill, net
Total assets	5,459,054	4,842,358
Current liabilities
Unearned revenue	248,530	172,753
Taxes payable	81,108	49,249
Accrued liabilities and other payables	2,249,432	2,163,066
Government grant	907,843	923,238
Loan from third parties	83,099	84,508
Operating lease liabilities	208,842	864,519
Due to related parties	1,679,188	1,226,885
Total current liabilities	5,945,973	5,964,450
Operating lease liabilities - non-current	1,901,857	789,489
Total liabilities	7,847,830	6,753,939
Stockholders’ deficit
Undesignated preferred stock, $0.001 par value, 20,000,000 shares authorized, none issued and outstanding
Common stock, par value $0.00001 per share, 500,000,000 shares authorized; 24,999,834 shares issued and outstanding as of March 31, 2024 and December 31, 2023	250	250
Additional paid in capital	15,068,308	14,975,423
Statutory reserve	151,988	151,988
Accumulated deficit	(17,823,992)	(17,220,392)
Accumulated other comprehensive income	214,670	181,150
Total stockholders’ deficit	(2,388,776)	(1,911,581)
Total liabilities and stockholders’ deficit	5,459,054	4,842,358
Nonrelated Party [Member]
Current liabilities
Accounts payable	487,931	478,456
Related Party [Member]
Current liabilities
Accounts payable		$ 1,776

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.001	$ 0.001
Undesignated preferred stock, shares authorized	20,000,000	20,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	24,999,834	24,999,834
Common stock, shares outstanding	24,999,834	24,999,834

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Sales revenue:
Total revenue, net	$ 851,559	$ 754,713
Operating costs and expenses
Cost of goods sold	327,811	175,488
Hotel operating costs	461,079	477,794
Selling	222,233	191,273
General and administrative	360,770	413,059
Provision for (reversal of) bad debts	8,027	(43,816)
Stock-based compensation	92,885	92,885
Total operating costs and expenses	1,472,805	1,306,683
Loss from operations	(621,246)	(551,970)
Non-operating income (expenses)
Interest income	114	289
Other income	18,802	24,861
Other expenses	(1,270)	(2,507)
Total non-operating income, net	17,646	22,643
Loss before income tax	(603,600)	(529,327)
Income tax expense		457
Net loss	(603,600)	(529,784)
Other comprehensive items
Foreign currency translation gain	33,520	24,542
Comprehensive loss	$ (570,080)	$ (505,242)
Loss per share - basic	$ (0.024)	$ (0.021)
Loss per share - diluted	$ (0.024)	$ (0.021)
Weighted average shares outstanding - basic	24,999,834	24,999,842
Weighted average shares outstanding - diluted	24,999,834	24,999,842
Products [Member]
Sales revenue:
Total revenue, net	$ 697,094	$ 422,296
Room Revenue [Member]
Sales revenue:
Total revenue, net	32,782	177,259
Food and Beverage Revenues [Member]
Sales revenue:
Total revenue, net	109,716	133,738
Other [Member]
Sales revenue:
Total revenue, net	$ 11,967	$ 21,420

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Statutory Reserves [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2022	$ 250	$ 14,458,583	$ 151,988	$ (15,249,858)	$ 172,849	$ (466,188)
Balance, shares at Dec. 31, 2022	24,999,842
Stock-based compensation		92,885				92,885
Net loss				(529,784)		(529,784)
Foreign currency translation gain					24,542	24,542
Disposal of subsidiary				120,160		120,160
Balance at Mar. 31, 2023	$ 250	14,551,468	151,988	(15,659,482)	197,391	(758,385)
Balance, shares at Mar. 31, 2023	24,999,842
Balance at Dec. 31, 2023	$ 250	14,975,423	151,988	(17,220,392)	181,150	(1,911,581)
Balance, shares at Dec. 31, 2023	24,999,834
Stock-based compensation		92,885				92,885
Net loss				(603,600)		(603,600)
Foreign currency translation gain					33,520	33,520
Balance at Mar. 31, 2024	$ 250	$ 15,068,308	$ 151,988	$ (17,823,992)	$ 214,670	$ (2,388,776)
Balance, shares at Mar. 31, 2024	24,999,834

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (603,600)	$ (529,784)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	106,299	104,561
Provision for (reversal of) bad debts	8,027	(43,816)
Provision for inventory reserve	9,405	18,502
Operating lease expense	233,070	210,334
Stock-based compensation	92,885	92,885
Deferred tax		457
Changes in assets and liabilities:
Other receivables and prepaid expenses	(20,080)	(50,416)
Advances to suppliers	(39,498)	49,587
Inventory	(35,192)	(200,787)
Security deposit	(70)
Unearned revenue	78,999	192,689
Taxes payable	32,823	(59,279)
Payment of lease liabilities	(325,498)	(186,473)
Accrued liabilities and other payables	124,299	(123,208)
Net cash used in operating activities	(461,451)	(472,681)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash disposed at disposal of subsidiary		(3,435)
Purchase of property and equipment	(41,053)	(1,746)
Net cash used in investing activities	(41,053)	(5,181)
CASH FLOWS FROM FINANCING ACTIVITIES:
Change in advance from related parties	383,802	437,560
Net cash provided by financing activities	383,802	437,560
EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(7,270)	2,836
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(125,972)	(37,466)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	466,966	619,900
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	340,994	582,434
Supplemental Cash flow data:
Income tax paid
Interest paid
Nonrelated Party [Member]
Changes in assets and liabilities:
Accounts receivable	(38,491)	176,944
Accounts payable	17,528	42,332
Related Party [Member]
Changes in assets and liabilities:
Accounts receivable	(100,603)
Accounts payable	$ (1,754)	$ (167,209)

ORGANIZATION AND DESCRIPTION OF BUSINESS

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Effective February 1, 2018, the Company changed its name to AiXin Life International, Inc. (“Aixin Life”).

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

Unaudited Interim Financial Information

Going Concern

● Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

● Raising cash through loans from related parties and potential equity offerings.

Global Uncertainties

Use of Estimates

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash

Accounts Receivable

The following table summarizes the activity related to the Company’s accounts receivable allowance for doubtful accounts for the three months ended March 31, 2024 and 2023:

	2024			2023
	For the three months ended March 31,
	2024			2023

Beginning balance	$	80,640		$	272,550
Provision for bad debts		8,027			-
Recoveries/Write offs		-			(43,816	)
Effect of translation		(1,380	)		1,342
Ending balance	$	87,287		$	230,076

Inventories

Property and Equipment

Office furniture			5 years
Electronic equipment			2-3 years
Machinery			3 years
Leasehold improvements			3 years
Vehicles			5 years

Impairment of Long-Lived Assets

Goodwill

Income Taxes

At March 31, 2024 and December 31, 2023, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

Revenue Recognition

	●	executed contract(s) with customers that the Company believes is legally enforceable;

	●	identification of performance obligation in the respective contract;

	●	determination of the transaction price for each performance obligation in the respective contract;

	●	allocation of the transaction price to each performance obligation; and

	●	recognition of revenue only when the Company satisfies each performance obligation.

The Company’s revenue recognition policies for its various operating segments are as follows:

Products

Hotel

Pharmacies

Manufacture and Sale

Unearned Revenue

Concentration of Credit Risk

The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

During the three months ended March 31, 2024 and 2023, the Company had no customer that accounted for over 10% of its total revenue.

During the three months ended March 31, 2024, the Company had one major supplier that accounted for over 10% of its total purchases.

Supplier		Net purchases for the three months ended March 31, 2024				% of total purchase
A		$	44,920				12	%

During the three months ended March 31, 2023, the Company had two major suppliers that accounted for over 10% of its total purchases.

Supplier	Net purchases for the three months ended March 31, 2023		% of total purchase
B	$	68,717		17	%
C		61,737		15	%

Leases

Statement of Cash Flows

Fair Value of Financial Instruments

Fair Value Measurements and Disclosures

	●	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

As of March 31, 2024 and December 31, 2023, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

Foreign Currency Translation and Comprehensive Income (Loss)

Earnings per Share

Basic income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.

As of March 31, 2024 and December 31, 2023, the Company did not have any potentially dilutive instruments.

Stock-Based Compensation

Segment Reporting

The following table shows the Company’s operations by business segment for the three months ended March 31, 2024 and 2023.

SCHEDULE OF SEGMENTS INFORMATION

	2024			2023
	For the Three Months Ended March 31,
	2024			2023
Net revenue
Products	$	165,749		$	163,260
Pharmacies		241,118			223,516
Hotel		154,465			332,417
Manufacture and sale		290,227			35,520
Total revenues, net	$	851,559		$	754,713

Operating costs and expenses
Products
Cost of goods sold	$	19,708		$	34,734
Operating expenses		372,056			367,789
Pharmacies
Cost of goods sold		80,174			138,633
Operating expenses		110,870			188,996
Hotel
Hotel operating costs		461,079			477,794
Operating expenses		71,877			(8,885	)
Manufacture and sale
Cost of goods sold		227,929			2,121
Operating expenses		129,112			105,501
Total operating costs and expenses	$	1,472,805		$	1,306,683

Loss from operations
Products	$	(226,015	)	$	(239,263	)
Pharmacies		50,074			(104,113	)
Hotel		(378,491	)		(136,492	)
Manufacture and sale		(66,814	)		(72,102	)
Loss from operations	$	(621,246	)	$	(551,970	)

Segment assets	As of March 31, 2024		As of December 31, 2023
Products	$	268,081	$	270,932
Pharmacies		544,702		425,546
Hotel		2,270,083		1,654,165
Manufacture and sale		2,376,188		2,491,715
Total assets	$	5,459,054	$	4,842,358

New Accounting Pronouncements

OTHER RECEIVABLES AND PREPAID EXPENSES

3 Months Ended

Mar. 31, 2024

Receivables [Abstract]

OTHER RECEIVABLES AND PREPAID EXPENSES

3. OTHER RECEIVABLES AND PREPAID EXPENSES

Other receivables and prepaid expenses consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Deposits	$	40,383	$	8,978
Prepaid expenses, including related party (see Note 13)		106,413		128,378
Employees’ social insurance		9,447		8,667
Others		31,728		24,808
Total	$	187,971	$	170,831

ADVANCES TO SUPPLIERS

3 Months Ended

Mar. 31, 2024

Advances To Suppliers

ADVANCES TO SUPPLIERS

4. ADVANCES TO SUPPLIERS

INVENTORIES

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

INVENTORIES

5. INVENTORIES

Inventories consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INVENTORIES

	March 31, 2024		December 31, 2023
Raw material	$	110,218	$	114,005
Finished goods-health supplements		2,875		-
Drugs, pharmaceutical and nutritional products		358,387		324,588
Food and beverage, hotel supplies and consumables		75,439		81,969
Total	$	546,919	$	520,562
Less: reserve for inventory		87,503		79,464
Total inventories, net	$	459,416	$	441,098

PROPERTY AND EQUIPMENT, NET

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

6. PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Vehicles	$	443,854		$	451,381
Office furniture		80,434			80,612
Electronic equipment		25,493			25,899
Machinery		1,292,976			1,314,902
Leasehold improvements		1,110,548			1,125,581
Other		11,796			11,997
Total		2,965,101			3,010,372
Less: Accumulated depreciation		(1,413,890	)		(1,330,697	)
Property and equipment, net	$	1,551,211		$	1,679,675

Depreciation expense for the three months ended March 31, 2024 and 2023 was $105,842 and $104,400, respectively.

INTANGIBLE ASSET, NET

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSET, NET

7. INTANGIBLE ASSET, NET

Intangible asset consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INTANGIBLE ASSET

	March 31, 2024			December 31, 2023
Software	$	12,309		$	12,516
Less: Accumulated amortization		(8,911	)		(8,599	)
Intangible asset, net	$	3,398		$	3,917

Amortization expense for the three months ended March 31, 2024 and 2023 was $457 and $161, respectively.

TAXES PAYABLE

3 Months Ended

Mar. 31, 2024

Taxes Payable

TAXES PAYABLE

8. TAXES PAYABLE

Taxes payable consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF TAX PAYABLE

	March 31, 2024		December 31, 2023
Value-added	$	37,746	$	6,439
Income		29,498		29,998
City construction		2,520		1,423
Education		1,828		1,024
Other		9,516		10,365
Taxes payable	$	81,108	$	49,249

ACCRUED LIABILITIES AND OTHER PAYABLES

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

ACCRUED LIABILITIES AND OTHER PAYABLES

9. ACCRUED LIABILITIES AND OTHER PAYABLES

Accrued liabilities and other payables consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Accrued employees’ social insurance	$	214,820	$	231,983
Accrued payroll and commission		434,773		308,768
Accrued rent expense		3,980		-
Construction payable		1,200,585		1,229,775
Payable for equipment purchase		22,718		30,307
Accrued professional fees		298,570		250,505
Deposit		10,802		10,986
Other payables		63,184		100,742
Total	$	2,249,432	$	2,163,066

GOVERNMENT GRANT

3 Months Ended

Mar. 31, 2024

Government Assistance [Abstract]

GOVERNMENT GRANT

10. GOVERNMENT GRANT

LOAN FROM THIRD PARTIES

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

LOAN FROM THIRD PARTIES

11. LOAN FROM THIRD PARTIES

LEASE

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

LEASE

12. LEASE

AiXinZhonghong leases its office. The lease has a remaining lease term of approximately 4.16 years.

Aixin Shangyan Hotel leases its hotel premises under an operating lease arrangement. The leases have remaining lease terms of approximately 1 to 10 years.

Aixintang Pharmacies lease retail pharmacy stores under operating lease arrangements, with remaining lease terms of 0.71 to 2.42 years.

Balance sheet information related to the Company’s leases is presented below:

SCHEDULE OF OPERATING LEASE LIABILITIES

	March 31, 2024		December 31, 2023
Operating Leases
Operating lease right-of-use assets	$	2,125,320	$	1,576,814

Operating lease liabilities – current	$	208,842	$	864,519
Operating lease liability – non-current		1,901,857		789,489
Total operating lease liabilities	$	2,110,699	$	1,654,008

The following provides details of the Company’s lease expenses:

SCHEDULE OF OPERATING LEASE EXPENSES

	2024		2023
	Three Months Ended March 31,
	2024		2023
Operating lease expenses	$	233,070	$	210,334

Other information related to leases is presented below:

	Three Months Ended March 31,
	2024			2023
Cash Paid for Amounts Included In Measurement of Liabilities:
Operating cash flows from operating leases	$	325,498			186,473

Weighted Average Remaining Lease Term:
Operating leases		8.90 years			1.36 years

Weighted Average Discount Rate:
Operating leases		4.84	%		4.75	%

Maturities of lease liabilities were as follows:


For the year ending December 31:
2024 (excluding the three months ended March 31, 2024)	$	249,956
2025		328,117
2026		266,812
2027		229,907
2028		225,060
Thereafter		1,341,088
Total lease payments		2,640,940
Less: imputed interest		(530,241	)
Total lease liabilities		2,110,699
Less: current portion		(208,842	)
Lease liabilities – non-current portion	$	1,901,857

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

13. RELATED PARTY TRANSACTIONS

Accounts receivable – related party

Accounts receivable – related party consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	2,410	$	2,451
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		101,796		4,309
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		1,994		2,028
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		1,994		2,028
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		19,667		-
Xiaoyan Zhou		15,332		32,493
Chengdu Aixin International Travel Service Co., Ltd		41,519		43,083
Total	$	184,712	$	86,392

Sales revenue – related party

Sales revenue – related party consisted of the following for the periods indicated:


	Three Months Ended March 31,
	2024		2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd	$	19,943	$	-
Chengdu Aixin International Travel Service Co., Ltd		6,443		24,055
Total	$	26,386	$	24,055

Prepaid expense – related party

Prepaid expense – related party consisted of the following as of the periods indicated:

		March 31, 2024				December 31, 2023
Chengdu Aixin International Travel Service Co., Ltd		$	90,731			$	120,483

Chengdu Aixin International Travel Service Co., Ltd is owned by the Company’s CEO.

Accounts payable – related party

Accounts payable – related party consisted of the following as of the periods indicated:

		March 31, 2024				December 31, 2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd.		$	-			$	1,776

Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd. is an entity controlled by Quanzhong Lin, CEO of the Company.

Due from related parties

Due from related parties consisted of the following as of the periods indicated:

SCHEDULE OF RELATED PARTY TRANSACTIONS

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	554	$	563
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		83		85
Chengdu Zhiweibing Pharmacy Co., Ltd.		1,709		1,738
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		692		704
Sichuan Aixin Investment Co. Ltd		9,155		9,310
Sichuan Yunxi Tang Pharmacy Co., Ltd		83		-
Chengdu Hesheng Yuan Pharmacy Co., Led		130		-
Huiliang Jiao		49,545		-
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		40,486		-
Total	$	102,437	$	12,400

Due to related parties

Due to related parties consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Quanzhong Lin	$	1,534,932	$	1,051,429
Yirong Shen		85,869		87,325
Huiliang Jiao		-		82,152
Tianfeng Li		-		780
Mianyang Aixin Cunshan Pharmacy Co. Ltd		110		112
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		53,275		-
Chengdu Aixin International travel service Co, Ltd		5,002		5,087
Total	$	1,679,188	$	1,226,885

Office leases

INCOME TAXES

3 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

INCOME TAXES

14. INCOME TAXES

China has a tax rate of 25% for all enterprises (including foreign-invested enterprises).

Uncertain Tax Positions

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

STOCKHOLDERS’ EQUITY

15. STOCKHOLDERS’ EQUITY

The Company is authorized to issue 20,000,000 shares of blank check preferred stock at $0.001 par value and 500,000,000 shares of common stock at $.00001 par value per share.

All share and earnings per share information has been retroactively adjusted to reflect the reverse stock split.

As of March 31, 2024 and December 31, 2023, the Company had 24,999,834 common shares issued and outstanding, after reverse stock split adjustment.

Stock Awards Issued for Services

Capital Contribution

STATUTORY RESERVES

3 Months Ended

Mar. 31, 2024

Statutory Reserves

STATUTORY RESERVES

16. STATUTORY RESERVES

Surplus reserve fund

Common welfare fund

OPERATING CONTINGENCIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

OPERATING CONTINGENCIES

17. OPERATING CONTINGENCIES

Litigation

The Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results of operations or cash flows.

SUBSEQUENT EVENT

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENT

18. SUBSEQUENT EVENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

Unaudited Interim Financial Information

Unaudited Interim Financial Information

Going Concern

Going Concern

● Gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.

● Raising cash through loans from related parties and potential equity offerings.

Global Uncertainties

Global Uncertainties

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash

Restricted Cash

Accounts Receivable

Accounts Receivable

The following table summarizes the activity related to the Company’s accounts receivable allowance for doubtful accounts for the three months ended March 31, 2024 and 2023:

	2024			2023
	For the three months ended March 31,
	2024			2023

Beginning balance	$	80,640		$	272,550
Provision for bad debts		8,027			-
Recoveries/Write offs		-			(43,816	)
Effect of translation		(1,380	)		1,342
Ending balance	$	87,287		$	230,076

Inventories

Inventories

Property and Equipment

Property and Equipment

Office furniture			5 years
Electronic equipment			2-3 years
Machinery			3 years
Leasehold improvements			3 years
Vehicles			5 years

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Goodwill

Goodwill

Income Taxes

Income Taxes

At March 31, 2024 and December 31, 2023, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

Revenue Recognition

Revenue Recognition

	●	executed contract(s) with customers that the Company believes is legally enforceable;

	●	identification of performance obligation in the respective contract;

	●	determination of the transaction price for each performance obligation in the respective contract;

	●	allocation of the transaction price to each performance obligation; and

	●	recognition of revenue only when the Company satisfies each performance obligation.

The Company’s revenue recognition policies for its various operating segments are as follows:

Products

Hotel

Pharmacies

Manufacture and Sale

Unearned Revenue

Unearned Revenue

Concentration of Credit Risk

Concentration of Credit Risk

The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

During the three months ended March 31, 2024 and 2023, the Company had no customer that accounted for over 10% of its total revenue.

During the three months ended March 31, 2024, the Company had one major supplier that accounted for over 10% of its total purchases.

Supplier		Net purchases for the three months ended March 31, 2024				% of total purchase
A		$	44,920				12	%

During the three months ended March 31, 2023, the Company had two major suppliers that accounted for over 10% of its total purchases.

Supplier	Net purchases for the three months ended March 31, 2023		% of total purchase
B	$	68,717		17	%
C		61,737		15	%

Leases

Leases

Statement of Cash Flows

Statement of Cash Flows

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Measurements and Disclosures

Fair Value Measurements and Disclosures

	●	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

As of March 31, 2024 and December 31, 2023, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

Foreign Currency Translation and Comprehensive Income (Loss)

Foreign Currency Translation and Comprehensive Income (Loss)

Earnings per Share

Earnings per Share

Basic income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.

As of March 31, 2024 and December 31, 2023, the Company did not have any potentially dilutive instruments.

Stock-Based Compensation

Stock-Based Compensation

Segment Reporting

Segment Reporting

The following table shows the Company’s operations by business segment for the three months ended March 31, 2024 and 2023.

SCHEDULE OF SEGMENTS INFORMATION

	2024			2023
	For the Three Months Ended March 31,
	2024			2023
Net revenue
Products	$	165,749		$	163,260
Pharmacies		241,118			223,516
Hotel		154,465			332,417
Manufacture and sale		290,227			35,520
Total revenues, net	$	851,559		$	754,713

Operating costs and expenses
Products
Cost of goods sold	$	19,708		$	34,734
Operating expenses		372,056			367,789
Pharmacies
Cost of goods sold		80,174			138,633
Operating expenses		110,870			188,996
Hotel
Hotel operating costs		461,079			477,794
Operating expenses		71,877			(8,885	)
Manufacture and sale
Cost of goods sold		227,929			2,121
Operating expenses		129,112			105,501
Total operating costs and expenses	$	1,472,805		$	1,306,683

Loss from operations
Products	$	(226,015	)	$	(239,263	)
Pharmacies		50,074			(104,113	)
Hotel		(378,491	)		(136,492	)
Manufacture and sale		(66,814	)		(72,102	)
Loss from operations	$	(621,246	)	$	(551,970	)

Segment assets	As of March 31, 2024		As of December 31, 2023
Products	$	268,081	$	270,932
Pharmacies		544,702		425,546
Hotel		2,270,083		1,654,165
Manufacture and sale		2,376,188		2,491,715
Total assets	$	5,459,054	$	4,842,358

New Accounting Pronouncements

New Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE FOR DOUBTFUL ACCOUNTS

The following table summarizes the activity related to the Company’s accounts receivable allowance for doubtful accounts for the three months ended March 31, 2024 and 2023:

	2024			2023
	For the three months ended March 31,
	2024			2023

Beginning balance	$	80,640		$	272,550
Provision for bad debts		8,027			-
Recoveries/Write offs		-			(43,816	)
Effect of translation		(1,380	)		1,342
Ending balance	$	87,287		$	230,076

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIVES

Office furniture			5 years
Electronic equipment			2-3 years
Machinery			3 years
Leasehold improvements			3 years
Vehicles			5 years

SCHEDULE OF CONCENTRATION OF RISK BY RISK FACTORS

During the three months ended March 31, 2024, the Company had one major supplier that accounted for over 10% of its total purchases.

Supplier		Net purchases for the three months ended March 31, 2024				% of total purchase
A		$	44,920				12	%

During the three months ended March 31, 2023, the Company had two major suppliers that accounted for over 10% of its total purchases.

Supplier	Net purchases for the three months ended March 31, 2023		% of total purchase
B	$	68,717		17	%
C		61,737		15	%

SCHEDULE OF SEGMENTS INFORMATION

The following table shows the Company’s operations by business segment for the three months ended March 31, 2024 and 2023.

SCHEDULE OF SEGMENTS INFORMATION

	2024			2023
	For the Three Months Ended March 31,
	2024			2023
Net revenue
Products	$	165,749		$	163,260
Pharmacies		241,118			223,516
Hotel		154,465			332,417
Manufacture and sale		290,227			35,520
Total revenues, net	$	851,559		$	754,713

Operating costs and expenses
Products
Cost of goods sold	$	19,708		$	34,734
Operating expenses		372,056			367,789
Pharmacies
Cost of goods sold		80,174			138,633
Operating expenses		110,870			188,996
Hotel
Hotel operating costs		461,079			477,794
Operating expenses		71,877			(8,885	)
Manufacture and sale
Cost of goods sold		227,929			2,121
Operating expenses		129,112			105,501
Total operating costs and expenses	$	1,472,805		$	1,306,683

Loss from operations
Products	$	(226,015	)	$	(239,263	)
Pharmacies		50,074			(104,113	)
Hotel		(378,491	)		(136,492	)
Manufacture and sale		(66,814	)		(72,102	)
Loss from operations	$	(621,246	)	$	(551,970	)

Segment assets	As of March 31, 2024		As of December 31, 2023
Products	$	268,081	$	270,932
Pharmacies		544,702		425,546
Hotel		2,270,083		1,654,165
Manufacture and sale		2,376,188		2,491,715
Total assets	$	5,459,054	$	4,842,358

OTHER RECEIVABLES AND PREPAID EXPENSES (Tables)

3 Months Ended

Mar. 31, 2024

Receivables [Abstract]

SCHEDULE OF OTHER RECEIVABLES AND PREPAID EXPENSES

Other receivables and prepaid expenses consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Deposits	$	40,383	$	8,978
Prepaid expenses, including related party (see Note 13)		106,413		128,378
Employees’ social insurance		9,447		8,667
Others		31,728		24,808
Total	$	187,971	$	170,831

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

SCHEDULE OF INVENTORIES

Inventories consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INVENTORIES

	March 31, 2024		December 31, 2023
Raw material	$	110,218	$	114,005
Finished goods-health supplements		2,875		-
Drugs, pharmaceutical and nutritional products		358,387		324,588
Food and beverage, hotel supplies and consumables		75,439		81,969
Total	$	546,919	$	520,562
Less: reserve for inventory		87,503		79,464
Total inventories, net	$	459,416	$	441,098

PROPERTY AND EQUIPMENT, NET (Tables)

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Vehicles	$	443,854		$	451,381
Office furniture		80,434			80,612
Electronic equipment		25,493			25,899
Machinery		1,292,976			1,314,902
Leasehold improvements		1,110,548			1,125,581
Other		11,796			11,997
Total		2,965,101			3,010,372
Less: Accumulated depreciation		(1,413,890	)		(1,330,697	)
Property and equipment, net	$	1,551,211		$	1,679,675

INTANGIBLE ASSET, NET (Tables)

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

SCHEDULE OF INTANGIBLE ASSET

Intangible asset consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF INTANGIBLE ASSET

	March 31, 2024			December 31, 2023
Software	$	12,309		$	12,516
Less: Accumulated amortization		(8,911	)		(8,599	)
Intangible asset, net	$	3,398		$	3,917

TAXES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2024

Taxes Payable

SCHEDULE OF TAX PAYABLE

Taxes payable consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF TAX PAYABLE

	March 31, 2024		December 31, 2023
Value-added	$	37,746	$	6,439
Income		29,498		29,998
City construction		2,520		1,423
Education		1,828		1,024
Other		9,516		10,365
Taxes payable	$	81,108	$	49,249

ACCRUED LIABILITIES AND OTHER PAYABLES (Tables)

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

SCHEDULE OF ACCRUED LIABILITIES AND OTHER PAYABLES

Accrued liabilities and other payables consisted of the following at March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
Accrued employees’ social insurance	$	214,820	$	231,983
Accrued payroll and commission		434,773		308,768
Accrued rent expense		3,980		-
Construction payable		1,200,585		1,229,775
Payable for equipment purchase		22,718		30,307
Accrued professional fees		298,570		250,505
Deposit		10,802		10,986
Other payables		63,184		100,742
Total	$	2,249,432	$	2,163,066

LEASE (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

SCHEDULE OF OPERATING LEASE LIABILITIES

Balance sheet information related to the Company’s leases is presented below:

SCHEDULE OF OPERATING LEASE LIABILITIES

	March 31, 2024		December 31, 2023
Operating Leases
Operating lease right-of-use assets	$	2,125,320	$	1,576,814

Operating lease liabilities – current	$	208,842	$	864,519
Operating lease liability – non-current		1,901,857		789,489
Total operating lease liabilities	$	2,110,699	$	1,654,008

SCHEDULE OF OPERATING LEASE EXPENSES

The following provides details of the Company’s lease expenses:

SCHEDULE OF OPERATING LEASE EXPENSES

	2024		2023
	Three Months Ended March 31,
	2024		2023
Operating lease expenses	$	233,070	$	210,334

SCHEDULE OF OTHER INFORMATION RELATED LEASES

Other information related to leases is presented below:

	Three Months Ended March 31,
	2024			2023
Cash Paid for Amounts Included In Measurement of Liabilities:
Operating cash flows from operating leases	$	325,498			186,473

Weighted Average Remaining Lease Term:
Operating leases		8.90 years			1.36 years

Weighted Average Discount Rate:
Operating leases		4.84	%		4.75	%

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

Maturities of lease liabilities were as follows:


For the year ending December 31:
2024 (excluding the three months ended March 31, 2024)	$	249,956
2025		328,117
2026		266,812
2027		229,907
2028		225,060
Thereafter		1,341,088
Total lease payments		2,640,940
Less: imputed interest		(530,241	)
Total lease liabilities		2,110,699
Less: current portion		(208,842	)
Lease liabilities – non-current portion	$	1,901,857

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2024

SCHEDULE OF ACCOUNTS RECEIVABLE - RELATED PARTY

Accounts receivable – related party consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	2,410	$	2,451
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		101,796		4,309
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		1,994		2,028
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		1,994		2,028
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		19,667		-
Xiaoyan Zhou		15,332		32,493
Chengdu Aixin International Travel Service Co., Ltd		41,519		43,083
Total	$	184,712	$	86,392

SCHEDULE OF SALES REVENUE RELATED PARTY

Sales revenue – related party consisted of the following for the periods indicated:


	Three Months Ended March 31,
	2024		2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd	$	19,943	$	-
Chengdu Aixin International Travel Service Co., Ltd		6,443		24,055
Total	$	26,386	$	24,055

SCHEDULE OF PREPAID EXPENSES AND ACCOUNTS PAYABLE RELATED PARTY

		March 31, 2024				December 31, 2023
Chengdu Aixin International Travel Service Co., Ltd		$	90,731			$	120,483

Chengdu Aixin International Travel Service Co., Ltd is owned by the Company’s CEO.

Accounts payable – related party

Accounts payable – related party consisted of the following as of the periods indicated:

		March 31, 2024				December 31, 2023
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd.		$	-			$	1,776

Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd. is an entity controlled by Quanzhong Lin, CEO of the Company.

SCHEDULE OF RELATED PARTY TRANSACTIONS

Due from related parties consisted of the following as of the periods indicated:

SCHEDULE OF RELATED PARTY TRANSACTIONS

	March 31, 2024		December 31, 2023
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd.	$	554	$	563
Chengdu Fuxiang Tang Pharmacy Co., Ltd.		83		85
Chengdu Zhiweibing Pharmacy Co., Ltd.		1,709		1,738
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd		692		704
Sichuan Aixin Investment Co. Ltd		9,155		9,310
Sichuan Yunxi Tang Pharmacy Co., Ltd		83		-
Chengdu Hesheng Yuan Pharmacy Co., Led		130		-
Huiliang Jiao		49,545		-
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd.		40,486		-
Total	$	102,437	$	12,400

Due to related parties

Due to related parties consisted of the following as of the periods indicated:

	March 31, 2024		December 31, 2023
Quanzhong Lin	$	1,534,932	$	1,051,429
Yirong Shen		85,869		87,325
Huiliang Jiao		-		82,152
Tianfeng Li		-		780
Mianyang Aixin Cunshan Pharmacy Co. Ltd		110		112
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd		53,275		-
Chengdu Aixin International travel service Co, Ltd		5,002		5,087
Total	$	1,679,188	$	1,226,885

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)	Feb. 17, 2023 $ / shares shares	Jul. 19, 2022 USD ($)	Jul. 19, 2022 CNY (¥)	Jun. 02, 2021 USD ($)	Jun. 02, 2021 CNY (¥)	May 25, 2021 USD ($)	May 25, 2021 CNY (¥)	Feb. 02, 2017 USD ($)	Mar. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 12, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1 for 2 reverse stock split
Common stock, par value \| $ / shares	$ 0.00001								$ 0.00001	$ 0.00001
Common stock, shares, outstanding \| shares	24,999,834								24,999,834	24,999,834
Aixin Shangyan Hotel Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business combination consideration transferred						$ 1,160,000	¥ 7,598,887
Chengdu Aixintang Pharmacy Co Ltd [Member] \| Pharmacies Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business acquisition, description of acquired entity				On June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Pharmacies Purchase Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, “Aixintang Pharmacies”) and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owned in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling Li.	On June 2, 2021, AiXin HK entered into an Equity Transfer Agreement (the “Pharmacies Purchase Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (together, “Aixintang Pharmacies”) and its three shareholders, Quanzhong Lin, Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owned in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest was owned by Ting Li and Xiao Ling Li.
Aixintang Pharmacies [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business combination consideration transferred				$ 5,310,000	¥ 34,635,845
Yunnan Shengshengyuan Technology Co Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business combination consideration transferred		$ 4,418,095	¥ 31,557,820
Business combination, adjusted		$ 116,802
Yunnan Shengshengyuan Technology Co Ltd [Member] \| Transfer Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business acquisition, description of acquired entity		On July 19, 2022, AiXin HK entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, (“Yunnan Shengshengyuan”) and Yun Chen (together, the “Sellers”), the shareholders of Yunnan Runcangsheng Technology Company Ltd. (“Runcangsheng”). Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun Chen.	On July 19, 2022, AiXin HK entered into an Equity Transfer Agreement with Yunnan Shengshengyuan Technology Co., Ltd, (“Yunnan Shengshengyuan”) and Yun Chen (together, the “Sellers”), the shareholders of Yunnan Runcangsheng Technology Company Ltd. (“Runcangsheng”). Yunnan Shengshengyuan owns in excess of 95% of the outstanding equity of Runcangsheng. The remaining equity interest is owned by Yun Chen.
China Concentric Capital Group [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment, ownership percentage											71.00%
Equity Transfer Agreement [Member] \| Aixin Shangyan Hotel Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment, ownership percentage						100.00%	100.00%
China Concentric Capital Group [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock percentage								65.00%
Purchase price of common stock								$ 300,000

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Beginning balance	$ 80,640	$ 272,550
Provision for bad debts	8,027
Recoveries/Write offs		(43,816)
Effect of translation	(1,380)	1,342
Ending balance	$ 87,287	$ 230,076

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIVES (Details)	Mar. 31, 2024
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Electronic Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Electronic Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Machinery [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years

SCHEDULE OF CONCENTRATION OF RISK BY RISK FACTORS (Details) - Cost of Sales [Member] - Supplier Concentration Risk [Member] - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supplier A [Member]
Product Information [Line Items]
Net purchases	$ 44,920
Percentage of total purchase	12.00%
Supplier B [Member]
Product Information [Line Items]
Net purchases		$ 68,717
Percentage of total purchase		17.00%
Supplier C [Member]
Product Information [Line Items]
Net purchases		$ 61,737
Percentage of total purchase		15.00%

SCHEDULE OF SEGMENTS INFORMATION (Details) - USD ($)	3 Months Ended
SCHEDULE OF SEGMENTS INFORMATION (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Product Information [Line Items]
Total revenues, net	$ 851,559	$ 754,713
Operating expenses	1,472,805	1,306,683
Hotel operating costs	461,079	477,794
Total operating costs and expenses	1,472,805	1,306,683
Loss from operations	(621,246)	(551,970)
Total assets	5,459,054		$ 4,842,358
Product [Member]
Product Information [Line Items]
Total revenues, net	165,749	163,260
Cost of goods sold	19,708	34,734
Operating expenses	372,056	367,789
Loss from operations	(226,015)	(239,263)
Total assets	268,081		270,932
Pharmacies [Member]
Product Information [Line Items]
Total revenues, net	241,118	223,516
Cost of goods sold	80,174	138,633
Operating expenses	110,870	188,996
Loss from operations	50,074	(104,113)
Total assets	544,702		425,546
Hotel [Member]
Product Information [Line Items]
Total revenues, net	154,465	332,417
Operating expenses	71,877	(8,885)
Hotel operating costs	461,079	477,794
Loss from operations	(378,491)	(136,492)
Total assets	2,270,083		1,654,165
Manufacture and Sale [Member]
Product Information [Line Items]
Total revenues, net	290,227	35,520
Cost of goods sold	227,929	2,121
Operating expenses	129,112	105,501
Loss from operations	(66,814)	$ (72,102)
Total assets	$ 2,376,188		$ 2,491,715

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Product Information [Line Items]
Net loss	$ (603,600)	$ (529,784)
Net Cash Provided by (Used in) Operating Activities	(461,451)	(472,681)
Retained Earnings (Accumulated Deficit)	(17,823,992)			$ (17,220,392)
Cash and Cash Equivalents, at Carrying Value	305,027			443,758
Accounts receivable, allowance for credit loss	87,287	230,076		80,640	$ 272,550
Inventory reserve	$ 9,405	$ 18,502
Property, plant and equipment, salvage value, percentage	5.00%		5.00%
Goodwill
Cash, FDIC Insured Amount	72,500		¥ 500,000
Uninsured deposits	$ 133,279			$ 289,059
Product [Member]
Product Information [Line Items]
VAT of sales price percentage	13.00%
Hotel [Member]
Product Information [Line Items]
VAT of sales price percentage	6.00%
Health Care [Member] \| Minimum [Member]
Product Information [Line Items]
VAT of sales price percentage	0.00%
Health Care [Member] \| Maximum [Member]
Product Information [Line Items]
VAT of sales price percentage	13.00%
Manufacture and Sale [Member]
Product Information [Line Items]
VAT of sales price percentage	13.00%

SCHEDULE OF OTHER RECEIVABLES AND PREPAID EXPENSES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Receivables [Abstract]
Deposits	$ 40,383	$ 8,978
Prepaid expenses, including related party (see Note 13)	106,413	128,378
Employees’ social insurance	9,447	8,667
Others	31,728	24,808
Total	$ 187,971	$ 170,831

ADVANCES TO SUPPLIERS (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Advances To Suppliers
Advances to suppliers	$ 225,294	$ 152,563

SCHEDULE OF INVENTORIES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw material	$ 110,218	$ 114,005
Finished goods-health supplements	2,875
Drugs, pharmaceutical and nutritional products	358,387	324,588
Food and beverage, hotel supplies and consumables	75,439	81,969
Total	546,919	520,562
Less: reserve for inventory	87,503	79,464
Total inventories, net	$ 459,416	$ 441,098

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total	$ 2,965,101	$ 3,010,372
Less: Accumulated depreciation	(1,413,890)	(1,330,697)
Property and equipment, net	1,551,211	1,679,675
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	443,854	451,381
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Total	80,434	80,612
Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	25,493	25,899
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total	1,292,976	1,314,902
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	1,110,548	1,125,581
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment [Line Items]
Total	$ 11,796	$ 11,997

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 105,842	$ 104,400

SCHEDULE OF INTANGIBLE ASSET (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Software	$ 12,309	$ 12,516
Less: Accumulated amortization	(8,911)	(8,599)
Intangible asset, net	$ 3,398	$ 3,917

INTANGIBLE ASSET, NET (Details Narrative) - USD ($)	3 Months Ended
INTANGIBLE ASSET, NET (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 457	$ 161

SCHEDULE OF TAX PAYABLE (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Taxes Payable
Value-added	$ 37,746	$ 6,439
Income	29,498	29,998
City construction	2,520	1,423
Education	1,828	1,024
Other	9,516	10,365
Taxes payable	$ 81,108	$ 49,249

SCHEDULE OF ACCRUED LIABILITIES AND OTHER PAYABLES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued employees’ social insurance	$ 214,820	$ 231,983
Accrued payroll and commission	434,773	308,768
Accrued rent expense	3,980
Construction payable	1,200,585	1,229,775
Payable for equipment purchase	22,718	30,307
Accrued professional fees	298,570	250,505
Deposit	10,802	10,986
Other payables	63,184	100,742
Total	$ 2,249,432	$ 2,163,066

GOVERNMENT GRANT (Details Narrative)	Dec. 01, 2021 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 01, 2021 CNY (¥)
Government Assistance [Abstract]
Transaction duration	10 years
Government contribution	$ 1,194,400			¥ 8,000,000
Government grant received		$ 907,843	$ 923,238

LOAN FROM THIRD PARTIES (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Loan from third parties	$ 83,099	$ 84,508

SCHEDULE OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease right-of-use assets	$ 2,125,320	$ 1,576,814
Operating lease liabilities – current	208,842	864,519
Operating lease liability – non-current	1,901,857	789,489
Total operating lease liabilities	$ 2,110,699	$ 1,654,008

SCHEDULE OF OPERATING LEASE EXPENSES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease expenses	$ 233,070	$ 210,334

SCHEDULE OF OTHER INFORMATION RELATED LEASES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating cash flows from operating leases	$ 325,498	$ 186,473
Weighted average operating lease term	8 years 10 months 24 days	1 year 4 months 9 days
Weighted average operating lease discount rate	4.84%	4.75%

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (excluding the three months ended March 31, 2024)	$ 249,956
2025	328,117
2026	266,812
2027	229,907
2028	225,060
Thereafter	1,341,088
Total lease payments	2,640,940
Less: imputed interest	(530,241)
Total operating lease liabilities	2,110,699	$ 1,654,008
Less: current portion	(208,842)	(864,519)
Lease liabilities – non-current portion	$ 1,901,857	$ 789,489

LEASE (Details Narrative)	3 Months Ended
LEASE (Details Narrative)	Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]
Expiration date	Dec. 31, 2024
AiXinZhonghong Biological Technology Co., Ltd., [Member]
Restructuring Cost and Reserve [Line Items]
Remaining lease term	4 years 1 month 28 days
Aixin Shangyan Hotel Management [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Remaining lease term	1 year
Aixin Shangyan Hotel Management [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Remaining lease term	10 years
Aixintang Pharmacies [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Remaining lease term	8 months 15 days
Aixintang Pharmacies [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Remaining lease term	2 years 5 months 1 day

SCHEDULE OF ACCOUNTS RECEIVABLE - RELATED PARTY (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Total	$ 184,712	$ 86,392
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	2,410	2,451
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	101,796	4,309
Chengdu Fuxiang Tang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	1,994	2,028
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	1,994	2,028
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	19,667
Xiaoyan Zhou [Member]
Related Party Transaction [Line Items]
Total	15,332	32,493
Chengdu Aixin International Travel Service Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	$ 41,519	$ 43,083

SCHEDULE OF SALES REVENUE RELATED PARTY (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transaction [Line Items]
Total	$ 26,386	$ 24,055
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	19,943
Chengdu Aixin International Travel Service Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	$ 6,443	$ 24,055

SCHEDULE OF PREPAID EXPENSES AND ACCOUNTS PAYABLE RELATED PARTY (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Prepaid expense - related party	$ 106,413	$ 128,378
Chengdu Aixin International Travel Service Co., Ltd [Member]
Related Party Transaction [Line Items]
Prepaid expense - related party	90,731	120,483
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd [Member]
Related Party Transaction [Line Items]
Advances and accounts payable to related party		$ 1,776

SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Total	$ 102,437	$ 12,400
Total	1,679,188	1,226,885
Chengdu WenJiang Aixin Nanjiang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	554	563
Chengdu Fuxiang Tang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	83	85
Chengdu Zhiweibing Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	1,709	1,738
Chengdu Wenjiang district Heneng hupu Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	692	704
Sichuan Aixin Investment Co. Ltd [Member]
Related Party Transaction [Line Items]
Total	9,155	9,310
Sichuan Yunxi Tang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	83
Chengdu Hesheng Yuan Pharmacy Co., Led [Member]
Related Party Transaction [Line Items]
Total	130
Huiliang Jiao [Member]
Related Party Transaction [Line Items]
Total	49,545
Total		82,152
Chengdu Lisheng Huiren Tang Pharmacy Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	40,486
Quanzhong Lin [Member]
Related Party Transaction [Line Items]
Total	1,534,932	1,051,429
Yirong Shen [Member]
Related Party Transaction [Line Items]
Total	85,869	87,325
Tianfeng Li [Member]
Related Party Transaction [Line Items]
Total		780
Mianyang Aixin Cunshan Pharmacy Co. Ltd [Member]
Related Party Transaction [Line Items]
Total	110	112
Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	53,275
Chengdu Aixin International Travel Service Co., Ltd [Member]
Related Party Transaction [Line Items]
Total	$ 5,002	$ 5,087

RELATED PARTY TRANSACTIONS (Details Narrative)	1 Months Ended			3 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative)	Jul. 31, 2023 CNY (¥)	May 31, 2014 USD ($)	May 31, 2014 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2024 CNY (¥)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future annual minimum lease payment, 2024				$ 249,956
Future annual minimum lease payment, 2025				328,117
Future annual minimum lease payment, 2026				266,812
Future annual minimum lease payment, 2027				229,907
Future annual minimum lease payment, 2028				$ 225,060
Lease expiration date				Dec. 31, 2024	Dec. 31, 2024
Office Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease term		3 years	3 years
Payment for rent		$ 704	¥ 5,000
Future annual minimum lease payment, 2024				$ 6,260
Future annual minimum lease payment, 2025				8,346
Future annual minimum lease payment, 2026				8,346
Future annual minimum lease payment, 2027				8,346
Future annual minimum lease payment, 2028				3,478
Office Leases [Member] \| Yunnan Runcangsheng Technology Company Ltd. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for rent				690	¥ 5,000
Office Leases [Member] \| Xiaoyan Zhou [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for rent \| ¥	¥ 2,000
Lease expiration date	Jan. 01, 2024
Office Leases [Member] \| Xiaoyan Zhou [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for rent				$ 414	¥ 3,000
Office Leases [Member] \| Renewed [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for rent		$ 704	¥ 5,000

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Unrecognized tax benefits	$ 0	$ 0
Foreign Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Effective income tax rate	25.00%

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)			3 Months Ended		12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Oct. 24, 2019	Oct. 22, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 17, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock shares authorized			20,000,000		20,000,000
Preferred stock,par value			$ 0.001		$ 0.001
Common stock, shares authorized			500,000,000		500,000,000
Common stock, par value			$ 0.00001		$ 0.00001	$ 0.00001
Reverse stock split			24,999,834
Common stock shares issued			24,999,834		24,999,834
Common stock shares outstanding			24,999,834		24,999,834	24,999,834
Stock based compensation			$ 92,885	$ 92,885
Unrecognized compensation expenses			$ 208,242
Employee services expected to be recognized			6 months 21 days
Yunnan Shengshengyuan Technology Co Ltd [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from contributed capital					$ 145,300
Employees and Contractors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock awards vest over			5 years
Share based payment award, description			the grantee will forfeit 80% of Shares Granted if no longer employed by or contracted with the Company on the date that is one year from the grant date, forfeit 60% of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from the grant date, forfeit 40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years from the grant date, and forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four years from the grant date. Effective on the 5th year from the grant date, none of the shares will be subject to forfeiture.
Employees and Contractors [Member] \| 2019 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares	275,000	18,750
Issuance of value	$ 1,520,200	$ 337,500
Price per share	$ 5.528	$ 18
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock shares issued			24,999,834		24,999,834
Common stock shares outstanding			24,999,834		24,999,834

STATUTORY RESERVES (Details Narrative) - USD ($)	3 Months Ended
STATUTORY RESERVES (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Net income transfer, rate	10.00%
Capital reserve, rate	50.00%
Statutory reserve fund	$ 0	$ 0
Minimum [Member]
Net income transfer, rate	5.00%
Capital reserve, rate	25.00%
Maximum [Member]
Net income transfer, rate	10.00%

OPERATING CONTINGENCIES (Details Narrative)			1 Months Ended
OPERATING CONTINGENCIES (Details Narrative)	Jun. 13, 2023 USD ($)	Jun. 13, 2023 CNY (¥)	Apr. 30, 2021 USD ($)	Apr. 30, 2021 CNY (¥)	Oct. 31, 2020 USD ($)	Oct. 31, 2020 CNY (¥)
Loss Contingencies [Line Items]
Purchase commitment amount					$ 392,305	¥ 2,500,000
Litigation settlement expense					$ 392,305	¥ 2,500,000
First Execution of Judgement [Member]
Loss Contingencies [Line Items]
Litigation settlement amount			$ 97,748	¥ 694,000
Litigation settlement interest	$ 139,692	¥ 991,800
Restoration of Execution [Member]
Loss Contingencies [Line Items]
Litigation settlement amount	$ 110,818	¥ 786,800
Frozen Case [Member]
Loss Contingencies [Line Items]
Litigation settlement amount			44,292	319,805
Gain loss litigation settlement			$ 212,412	¥ 1,510,000

AiXin Life (QX) (USOTC:AIXND)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more AiXin Life (QX) Charts.

AiXin Life (QX) (USOTC:AIXND)
Historical Stock Chart
From Jun 2023 to Jun 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AIXND AiXin Life International Inc (QX)

AiXin Life International Inc (QX) News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AIXND AiXin Life International Inc (QX)

AiXin Life International Inc (QX) News

Your Recent History

Company

Business

Popular

Get The App